SLBS Medical college Mandi at Ner Chowk

Opening Hours : Monday to Saturday - 9am to 5pm
  Contact : 01905-243950

Department Category of Post Name
Pharmacology Professor Dr. Parveen Kumar Sharma
Associate Professor Dr. Harpreet Singh
Assistant Professor Dr. Aradhna Sharma
Dr. Shivani Bhagat
Tutor Dr. Anup Kumar
Dr. Rajan Negi

Competency and Objectives

Number COMPETENCY Domain Level Core Suggested Teaching Suggested Assessment Number required Vertical Integration Horizontal Integration
The student should be able to K/S/A/C K/KH/S (Y/N) Learning method method to certify P
H/P
PH1.1 Define and describe the principles of pharmacology and pharmacotherapeutics K K Y Lecture Written/ Viva voce
Obj. 1 At the end of session a phase II student must be able to define pharmacology K K Y Lecture Written/ Viva voce
Obj. 2 At the end of session a phase II student must be able to define pharmacotherapeutics K K Y Lecture Written/ Viva voce
Obj. 3 At the end of session a phase II student must be able to  define clinical pharmacology K K Y Lecture Written/ Viva voce
Obj. 4 At the end of session a phase II student must be able to define  pharmacy K K Y Lecture Written/ Viva voce
Obj. 5 At the end of session a phase II student must be able to define  toxicology K K Y Lecture Written/ Viva voce
Obj. 6 At the end of session a phase II student must be able to define a drug K K Y Lecture Written/ Viva voce
Obj. 7 At the end of session a phase II student must be able to define a prodrug K K Y Lecture Written/ Viva voce
Obj. 8 At the end of session a phase II student must be able to define active pharmaceutical ingredient K K Y Lecture Written/ Viva voce
PH1.2 Describe the basis of Evidence based medicine and Therapeutic drug monitoring K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of session a phase II student must be able to define evidence based medicine K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of session a phase II student must be able to descibe the four cardinal components of tharapeutic evaluation of a drug K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of session a phase II student must be able to describe clinical trial K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of session a phase II student must be able to decscribe ethical  principles  in a clinical trial  K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of session a phase II student must be able to describe a controlled trial  K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of session a phase II student must be able to descibe the designs of a controlled trial  K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of session a phase II student must be able to describe randomisation in aclinical trial K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of session a phase II student must be able to describe  blinding in a clinical trial K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of session a phase II student must be able to types of blinidingin aclinical trial K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of session a phase II student must be able to define a open trial K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of session a phase II student must be able to inclusion/ exclusion criteria of subject selection in a clinical trial K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of session a phase II student must be able to define primary end point of a clinical trial K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of session a phase II student must be able to define secondary end point of an clinical trial K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of session a phase II student must be able to decscibe a cohort study K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of session a phase II student must be able to describe a case control study K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of session a phase II student must be able to define a meta analysis K KH Y Lecture Written/ Viva voce
PH1.3 Enumerate and identify drug formulations and drug delivery systems K/S SH Y DOAP SKILL ASSESSMENT
Obj. 1 At the end of session a phase II student must be able to define a drug formulation K/S SH Y DOAP SKILL ASSESSMENT
Obj. 2 At the end of session a phase II student must be able to define drug dosage K/S SH Y DOAP SKILL ASSESSMENT
Obj. 3 At the end of session a phase II student must be able to enumerate types of drug formulations K/S SH Y DOAP SKILL ASSESSMENT
Obj. 4 At the end of session a phase II student must be able to describe advantages of various drug formulations K/S SH Y DOAP SKILL ASSESSMENT
Obj. 5 At the end of session a phase II student must be able to describe disadvantages of various drug formulations K/S SH Y DOAP SKILL ASSESSMENT
Obj. 6 At the end of session a phase II student must be able to enumerate types of common drug delivery systems K/S SH Y DOAP SKILL ASSESSMENT
Obj. 7 At the end of session a phase II student must be able to describe various drug delivery systems K/S SH Y DOAP SKILL ASSESSMENT
Obj. 8 At the end of session a phase II student must be able to describe advantages of various drug delivery systems K/S SH Y DOAP SKILL ASSESSMENT
Obj. 9 At the end of session a phase II student must be able to identify various drug formulations  K/S SH Y DOAP SKILL ASSESSMENT
Obj. 10 At the end of session a phase II student must be able to demonstrate correct method of using  various drug delivery systems  K/S SH Y DOAP SKILL ASSESSMENT
PH1.4 Describe absorption, distribution, metabolism & excretion of drugs K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of session a phase II student must be able to define pharmacokinetics K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of session a phase II student must be able to describe mechanism of membrane transport K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of session a phase II student must be able to describe mechanism of passive diffusion of drugs K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of session a phase II student must be able to describe filteration as mechanism of drug transport K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of session a phase II student must be able to describe facillitated diffusion as mechanism of drug transport K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of session a phase II student must be able to describe primary active transport as mechanism of drug transport K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of session a phase II student must be able to  describe secondary active transport as mechanism of drug transport K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of session a phase II student must be able to describe endocytosis and exocytosis as mechanism of drug transport K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of session a phase II student must be able to define drug absorption K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of session a phase II student must be able to describe effect of aquous solubility on drug absorption K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of session a phase II student must be able to describe effect of concentration on drug absorption K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of session a phase II student must be able to describe effect of area of absorbing surface on drug absorption K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of session a phase II student must be able to describe effect of vascularity of absorbing surface on drug absorption K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of session a phase II student must be able to describe effect of route of administration on drug absorption K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of session a phase II student must be able to define bioavailability K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of session a phase II student must be able to describe time-concentration curve with respect to bioavailability K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of session a phase II student must be able to describe effect of route of administraion on bioavailability K KH Y Lecture Written/ Viva voce
Obj. 18 At the end of session a phase II student must be able to enumerate pharmaceutical factors affecting bioavailability K KH Y Lecture Written/ Viva voce
Obj. 19 At the end of session a phase II student must be able to define bioequivalence K KH Y Lecture Written/ Viva voce
Obj. 20 At the end of session a phase II student must be able to enumerate factors affecting bioequivalence K KH Y Lecture Written/ Viva voce
Obj. 21 At the end of session a phase II student must be able to define percentage difference in bioavailability acceptable to consider two drugs bioequivalent K KH Y Lecture Written/ Viva voce
Obj. 22 At the end of session a phase II student must be able to define drug distribution K KH Y Lecture Written/ Viva voce
Obj. 23 At the end of session a phase II student must be able to describe effect of lipid solubility on drug distribution K KH Y Lecture Written/ Viva voce
Obj. 24 At the end of session a phase II student must be able to describe effect of ionisation on drug distribution K KH Y Lecture Written/ Viva voce
Obj. 25 At the end of session a phase II student must be able to describe effect of protein binding on drug distribution K KH Y Lecture Written/ Viva voce
Obj. 26 At the end of session a phase II student must be able to describe effect of presence of tissue specific transporters on drug distribution K KH Y Lecture Written/ Viva voce
Obj. 27 At the end of session a phase II student must be able to describe effect of regional blood flow on drug distribution K KH Y Lecture Written/ Viva voce
Obj. 28 At the end of session a phase II student must be able to describe apparent volume of distribution K KH Y Lecture Written/ Viva voce
Obj. 29 At the end of session a phase II student must be able to write formula of apparent volume of distribution K KH Y Lecture Written/ Viva voce
Obj. 30 At the end of session a phase II student must be able to calculate apparent volume of distribution K KH Y Lecture Written/ Viva voce
Obj. 31 At the end of session a phase II student must be able to enumerate causes of large volume of distribution K KH Y Lecture Written/ Viva voce
Obj. 32 At the end of session a phase II student must be able to enumerate causes of low volume of distribution K KH Y Lecture Written/ Viva voce
Obj. 33 At the end of session a phase II student must be able to define redistribution K KH Y Lecture Written/ Viva voce
Obj. 34 At the end of session a phase II student must be able to describe clinical implications of drug redistribution K KH Y Lecture Written/ Viva voce
Obj. 35 At the end of session a phase II student must be able to describe blood brain barrier K KH Y Lecture Written/ Viva voce
Obj. 36 At the end of session a phase II student must be able to describe the effects of blood brain barrier on drug distribution K KH Y Lecture Written/ Viva voce
Obj. 37 At the end of session a phase II student must be able to describe effects of blood CSF barrier on drug distribution K KH Y Lecture Written/ Viva voce
Obj. 38 At the end of session a phase II student must be able to  define enzymatic blood brain barrier K KH Y Lecture Written/ Viva voce
Obj. 39 At the end of session a phase II student must be able to describe implications of BBB deficient area of CNS on drug action K KH Y Lecture Written/ Viva voce
Obj. 40 At the end of session a phase II student must be able to describe mechanism of exit of drugs from CSF and Brain K KH Y Lecture Written/ Viva voce
Obj. 41 At the end of session a phase II student must be able to describe blood-placental barrier K KH Y Lecture Written/ Viva voce
Obj. 42 At the end of session a phase II student must be able to enumerate placental drug transporters K KH Y Lecture Written/ Viva voce
Obj. 43 At the end of session a phase II student must be able to implications of presence of placental drug transporters on drug action K KH Y Lecture Written/ Viva voce
Obj. 44 At the end of session a phase II student must be able to define plasma protein binding of drugs K KH Y Lecture Written/ Viva voce
Obj. 45 At the end of session a phase II student must be able to enumerate plasma proteins which binds to drugs K KH Y Lecture Written/ Viva voce
Obj. 46 At the end of session a phase II student must be able to enumerate highly plasma protein bound drugs K KH Y Lecture Written/ Viva voce
Obj. 47 At the end of session a phase II student must be able to enumerate drugs with low plasma protein binding K KH Y Lecture Written/ Viva voce
Obj. 48 At the end of session a phase II student must be able to describe clinincal implications of plasma protein binding K KH Y Lecture Written/ Viva voce
Obj. 49 At the end of session a phase II student must be able to define tissue storage of drugs K KH Y Lecture Written/ Viva voce
Obj. 50 At the end of session a phase II student must be able to enumerate drugs concentrated in skeletal muscle, heart, liver, kidney, thyroid, brain, retina, iris, bone, teeth, adipose tissue K KH Y Lecture Written/ Viva voce
Obj. 51 At the end of session a phase II student must be able to describe clinical implications of tissue storage of drugs K KH Y Lecture Written/ Viva voce
Obj. 52 At the end of session a phase II student must be able to define biotransformation K KH Y Lecture Written/ Viva voce
Obj. 53 At the end of session a phase II student must be able to define xenobiotics K KH Y Lecture Written/ Viva voce
Obj. 54 At the end of session a phase II student must be able to describe effect of biotransformation on drug movement through the body K KH Y Lecture Written/ Viva voce
Obj. 55 At the end of session a phase II student must be able to enumerate sites of drug metabolism K KH Y Lecture Written/ Viva voce
Obj. 56 At the end of session a phase II student must be able to describe effect of biotransformation on drug activity K KH Y Lecture Written/ Viva voce
Obj. 57 At the end of session a phase II student must be able to enumerate the prodrugs K KH Y Lecture Written/ Viva voce
Obj. 58 At the end of session a phase II student must be able to enumerate active metabolites of prodrugs listed above K KH Y Lecture Written/ Viva voce
Obj. 59 At the end of session a phase II student must be able to phases of biotransformation K KH Y Lecture Written/ Viva voce
Obj. 60 At the end of session a phase II student must be able to describe non-synthetic/phase I/ functionalization reactions K KH Y Lecture Written/ Viva voce
Obj. 61 At the end of session a phase II student must be able to describe synthetic/phase II/ conjugation reactions K KH Y Lecture Written/ Viva voce
Obj. 62 At the end of session a phase II student must be able to enumerate five types of non-synthetic reactions K KH Y Lecture Written/ Viva voce
Obj. 63 At the end of session a phase II student must be able to describe five types of non-synthetic reactions K KH Y Lecture Written/ Viva voce
Obj. 64 At the end of session a phase II student must be able to enumerate seven types of synthetic reactions K KH Y Lecture Written/ Viva voce
Obj. 65 At the end of session a phase II student must be able to describe seven types of synthetic reactions K KH Y Lecture Written/ Viva voce
Obj. 66 At the end of session a phase II student must be able to enumerate microsomal enzymes involved in biotransformation K KH Y Lecture Written/ Viva voce
Obj. 67 At the end of session a phase II student must be able to describe microsomal enzymes involved in biotransformation K KH Y Lecture Written/ Viva voce
Obj. 68 At the end of session a phase II student must be able to enumerate non-microsomal enzymes involved in biotransformation K KH Y Lecture Written/ Viva voce
Obj. 69 At the end of session a phase II student must be able to describe non-microsomal enzymes involved in biotransformation K KH Y Lecture Written/ Viva voce
Obj. 70 At the end of session a phase II student must be able to describe microsomal enzyme induction K KH Y Lecture Written/ Viva voce
Obj. 71 At the end of session a phase II student must be able to describe consequences of microsomal enzyme induction K KH Y Lecture Written/ Viva voce
Obj. 72 At the end of session a phase II student must be able to describe possible uses of microsomal enzyme induction K KH Y Lecture Written/ Viva voce
Obj. 73 At the end of session a phase II student must be able to define Hoffmann elimination K KH Y Lecture Written/ Viva voce
Obj. 74 At the end of session a phase II student must be able to define inhibition of drug metabolism K KH Y Lecture Written/ Viva voce
Obj. 75 At the end of session a phase II student must be able to describe inhibition of drug metabolism K KH Y Lecture Written/ Viva voce
Obj. 76 At the end of session a phase II student must be able to enumerate drugs that inhibit drug metabolizing enzymes K KH Y Lecture Written/ Viva voce
Obj. 77 At the end of session a phase II student must be able to define first pass metabolism (presystemic metabolism) K KH Y Lecture Written/ Viva voce
Obj. 78 At the end of session a phase II student must be able to describe first pass metabolism (presystemic metabolism) K KH Y Lecture Written/ Viva voce
Obj. 79 At the end of session a phase II student must be able to write formula of systemic bioavailability K KH Y Lecture Written/ Viva voce
Obj. 80 At the end of session a phase II student must be able to enumerate attributes of drugs with high first pass metabolism K KH Y Lecture Written/ Viva voce
Obj. 81 At the end of session a phase II student must be able to define excretion K KH Y Lecture Written/ Viva voce
Obj. 82 At the end of session a phase II student must be able to enumerate all routes of drug excretion K KH Y Lecture Written/ Viva voce
Obj. 83 At the end of session a phase II student must be able to differentiate drug elimination from drug excretion K KH Y Lecture Written/ Viva voce
Obj. 84 At the end of session a phase II student must be able to decribe all routes of drug excretion K KH Y Lecture Written/ Viva voce
Obj. 85 At the end of session a phase II student must be able to decribe entero-hepatic circulation of drugs K KH Y Lecture Written/ Viva voce
Obj. 86 At the end of session a phase II student must be able to describe various processes leading to renal drug excretion K KH Y Lecture Written/ Viva voce
Obj. 87 At the end of session a phase II student must be able to define clearance K KH Y Lecture Written/ Viva voce
Obj. 88 At the end of session a phase II student must be able to write down the formula for clearance K KH Y Lecture Written/ Viva voce
Obj. 89 At the end of session a phase II student must be able to describe first order kinetics with diagram K KH Y Lecture Written/ Viva voce
Obj. 90 At the end of session a phase II student must be able to describe zero order kinetics with diagram K KH Y Lecture Written/ Viva voce
Obj. 91 At the end of session a phase II student must be able to describe blood flow dependent elimination K KH Y Lecture Written/ Viva voce
Obj. 92 At the end of session a phase II student must be able to describe plasma t-half K KH Y Lecture Written/ Viva voce
Obj. 93 At the end of session a phase II student must be able to derive formula for plasma t=half  K KH Y Lecture Written/ Viva voce
Obj. 94 At the end of session a phase II student must be able to describe principles of kinetics in repeated drug administration K KH Y Lecture Written/ Viva voce
Obj. 95 At the end of session a phase II student must be able to describe plateu principle K KH Y Lecture Written/ Viva voce
Obj. 96 At the end of session a phase II student must be able to describe target level strategy K KH Y Lecture Written/ Viva voce
PH1.5 Describe general principles of mechanism of drug action K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of session a phase II student must be able to define pharmacodyanamics K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of session a phase II student must be able to define receptor K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of session a phase II student must be able to define class theory of receptor action K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of session a phase II student must be able to define phase theory of receptor action K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of session a phase II student must be able to enumerate non receptor mediated mechanisms of drug action K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of session a phase II student must be able to define agonist K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of session a phase II student must be able to define antagonist K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of session a phase II student must be able to define partial agonist K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of session a phase II student must be able to define inverse agonist K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of session a phase II student must be able to enumerate parts of G Protien coupled receptors K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of session a phase II student must be able to enumerate various G- Protiens K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of session a phase II student must be able to describe adenyl cyclase -cAMP dependent transduction pathway with examlpes K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of session a phase II student must be able to describe IP3 DAG dependent transduction pathway with examples K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of session a phase II student must be able to describe ion channel mediated transduction pathway with examples K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of session a phase II student must be able to describe receptor controlled ion- channel with examples K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of session a phase II student must be able to describe enzyme linked receptors with examples K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of session a phase II student must be able to describe receptor regulated gene expression with examples  K KH Y Lecture Written/ Viva voce
Obj. 18 At the end of session a phase II student must be able to enumerate four  function of receptor namely propagation, amplification, integration, transduction K KH Y Lecture Written/ Viva voce
Obj. 19 At the end of session a phase II student must be able to describe principles of basis of regulation of receptors  K KH Y Lecture Written/ Viva voce
Obj. 20 At the end of session a phase II student must be able to describe upregulation K KH Y Lecture Written/ Viva voce
Obj. 21 At the end of session a phase II student must be able to descibe downregulation K KH Y Lecture Written/ Viva voce
Obj. 22 At the end of session a phase II student must be able to describe principles of dose response curve with with appropriate diagrams K KH Y Lecture Written/ Viva voce
Obj. 23 At the end of session a phase II student must be able to descibe drug potency with Dose response curve K KH Y Lecture Written/ Viva voce
Obj. 24 At the end of session a phase II student must be able to descibe drug efficacy with Dose response curve K KH Y Lecture Written/ Viva voce
Obj. 25 At the end of session a phase II student must be able to write down formula for calculation of therapeutic index K KH Y Lecture Written/ Viva voce
Obj. 26 At the end of session a phase II student must be able to define lethal dose 50 (LD50) K KH Y Lecture Written/ Viva voce
Obj. 27 At the end of session a phase II student must be able to define effective dose 50 (ED50) K KH Y Lecture Written/ Viva voce
Obj. 28 At the end of session a phase II student must be able to Describe synergism with appropriate examples and diagrams K KH Y Lecture Written/ Viva voce
Obj. 29 At the end of session a phase II student must be able to define antagonism K KH Y Lecture Written/ Viva voce
Obj. 30 At the end of session a phase II student must be able to describe physical antagonism with appropriate examples and diagrams K KH Y Lecture Written/ Viva voce
Obj. 31 At the end of session a phase II student must be able to describe chemical antagonism with appropriate examples and diagrams K KH Y Lecture Written/ Viva voce
Obj. 32 At the end of session a phase II student must be able to describe physiological antagonism with appropriate examples and diagrams K KH Y Lecture Written/ Viva voce
Obj. 33 At the end of session a phase II student must be able to describe receptor antagonism with appropriate examples and diagrams K KH Y Lecture Written/ Viva voce
PH1.6 Describe Principles of Pharmacovigilance & ADR reporting systems K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of session a phase II student must be able to define pharmacovigillance K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of session a phase II student must be able to define adverse drug reaction K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of session a phase II student must be able to define adverse drug event K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of session a phase II student must be able to describe pharmacivigillance programme of india  K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of session a phase II student must be able to describe basic principles of causality assessment K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of session a phase II student must be able to describe basic principles of management of adverse drug reactions K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of session a phase II student must be able to WHO scale of causality assessment K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of session a phase II student must be able to fill the WHO Adverse drug reaction form correctly based on given clinical situations K P Y DOAP SKILL ASSESMENT
PH1.7 Define, identify and describe the management of adverse drug reactions (ADR) K/S KH Y SGD Written/ Viva voce
Obj. 1 At the end of session a phase II student must be able to define side effect K/S KH Y SGD Written/ Viva voce
Obj. 2 At the end of session a phase II student must be able to define toxic effect K/S KH Y SGD Written/ Viva voce
Obj. 3 At the end of session a phase II student must be able to defferentiate between Adverse drug reaction and adverse drug event K/S KH Y SGD Written/ Viva voce
Obj. 4 At the end of session a phase II student must be able to dIfferentiate between Adverse drug reaction,side effect and toxic effect K/S KH Y SGD Written/ Viva voce
Obj. 5 At the end of session a phase II student must be able to classify adverse drug reaction depending upon their severity K/S KH Y SGD Written/ Viva voce
Obj. 6 At the end of session a phase II student must be able to enumerate types of adverse drug reactions K/S KH Y SGD Written/ Viva voce
Obj. 7 At the end of session a phase II student must be able to describe non proprietary name  K/S KH Y SGD Written/ Viva voce
Obj. 8 At the end of session a phase II student must be able to descibe common adverse drug reactions  K/S KH Y SGD Written/ Viva voce
Obj. 9 At the end of session a phase II student must be able to describe life threatening adverse drug reactions K/S KH Y SGD Written/ Viva voce
Obj. 10 At the end of session a phase II student must be able to identify common adverse drug reactions  K/S KH Y SGD, DOAP Written/ Viva voce
Obj. 11 At the end of session a phase II student must be able to identify life threatening adverse drug reactions  K/S KH Y SGD, DOAP Written/ Viva voce
Obj. 12 At the end of session a phase II student must be able to prescribe for common adverse drug reactions  K/S KH Y SGD, DOAP Written/ Viva voce
Obj. 13 At the end of session a phase II student must be able to prescribe for life threatening adverse drug reactions K/S KH Y SGD Written/ Viva voce
Obj. 14 At the end of session a phase II student must be able to describe risk categories of drugs during pregnancy K/S KH Y SGD Written/ Viva voce
Obj. 15 At the end of session a phase II student must be able to describe  side effect with common examples K/S KH Y SGD Written/ Viva voce
Obj. 16 At the end of session a phase II student must be able to describe secondary effects with common examples K/S KH Y SGD Written/ Viva voce
Obj. 17 At the end of session a phase II student must be able to describe Toxic effects with common examples K/S KH Y SGD Written/ Viva voce
Obj. 18 At the end of session a phase II student must be able to describe describe treatment of common toxic effects of drugs  K/S KH Y SGD Written/ Viva voce
Obj. 19 At the end of session a phase II student must be able to describe intolerance with common examples  K/S KH Y SGD Written/ Viva voce
Obj. 20 At the end of session a phase II student must be able to describe idiosyncracy with common examples K/S KH Y SGD Written/ Viva voce
Obj. 21 At the end of session a phase II student must be able to describe Drug allergy with commob examples K/S KH Y SGD Written/ Viva voce
Obj. 22 At the end of session a phase II student must be able to describe treatment of drug allergy K/S KH Y SGD Written/ Viva voce
Obj. 23 At the end of session a phase II student must be able to describe photosensitivity with common examlpes K/S KH Y SGD Written/ Viva voce
Obj. 24 At the end of session a phase II student must be able to describe treatment of phosensitivity reactions K/S KH Y SGD Written/ Viva voce
Obj. 25 At the end of session a phase II student must be able to define Drug dependence  K/S KH Y SGD Written/ Viva voce
Obj. 26 At the end of session a phase II student must be able to describe describe types of drug dependence K/S KH Y SGD Written/ Viva voce
Obj. 27 At the end of session a phase II student must be able to define drug abuse  K/S KH Y SGD Written/ Viva voce
Obj. 28 At the end of session a phase II student must be able to define drug addiction K/S KH Y SGD Written/ Viva voce
Obj. 29 At the end of session a phase II student must be able to define drug habituation K/S KH Y SGD Written/ Viva voce
Obj. 30 At the end of session a phase II student must be able to deffrentaite between drug addiction, drug abuse and drug habituation K/S KH Y SGD Written/ Viva voce
Obj. 31 At the end of session a phase II student must be able to describe drug withdrawl reactions K/S KH Y SGD Written/ Viva voce
Obj. 32 At the end of session a phase II student must be able to describe strategies to avoid drug withdrawl reactions K/S KH Y SGD Written/ Viva voce
Obj. 33 At the end of session a phase II student must be able to define  teratogenicity K/S KH Y SGD Written/ Viva voce
Obj. 34 At the end of session a phase II student must be able to describe teratogenicity K/S KH Y SGD Written/ Viva voce
Obj. 35 At the end of session a phase II student must be able to enumerate common human teratogenic drugs K/S KH Y SGD Written/ Viva voce
Obj. 36 At the end of session a phase II student must be able to describe risk categories of drugs during pregnancy K/S KH Y SGD Written/ Viva voce
Obj. 37 At the end of session a phase II student must be able to describe mutagenicity withexamples K/S KH Y SGD Written/ Viva voce
Obj. 38 At the end of session a phase II student must be able to describe carcinogenicity with examples K/S KH Y SGD Written/ Viva voce
Obj. 39 At the end of session a phase II student must be able to describe drug induced diseaSes with examples K/S KH Y SGD Written/ Viva voce
PH1.8 Identify and describe the management of drug interactions K/S KH Y SGD SKILL ASSESMENT
Obj. 1 At the end of session a phase II student must be able to define drug interactions K/S KH Y SGD SKILL ASSESMENT
Obj. 2 At the end of session a phase II student must be able to enumerate types of drug interactions K/S KH Y SGD SKILL ASSESMENT
Obj. 3 At the end of session a phase II student must be able to define pharmacokinetic drug interactions K/S KH Y SGD SKILL ASSESMENT
Obj. 4 At the end of session a phase II student must be able to define pharmacodynamic drug interactions K/S KH Y SGD SKILL ASSESMENT
Obj. 5 At the end of session a phase II student must be able to identify drug interactions K/S KH Y VAL SKILL ASSESMENT
Obj. 6 At the end of session a phase II student must be able to describe the management of drug interactions K/S KH Y VAL SKILL ASSESMENT
PH1.9 Describe nomenclature of drugs i.e. generic, branded drugs K/S SH Y Lecture Written/ Viva voce
Obj. 1 At the end of session a phase II student must be able to define chemical names of the drugs  K/S SH Y Lecture Written/ Viva voce
Obj. 2 At the end of session a phase II student must be able to define non propreitary names of drugs K/S SH Y Lecture Written/ Viva voce
Obj. 3 At the end of session a phase II student must be able to define proprietary ( brand) name K/S SH Y Lecture Written/ Viva voce
Obj. 4 At the end of session a phase II student must be able to describe   proprietary (brand) name  K/S SH Y Lecture Written/ Viva voce
Obj. 5 At the end of session a phase II student must be able to define drug compendia K/S SH Y Lecture Written/ Viva voce
Obj. 6 At the end of session a phase II student must be able to defferentiate chemical name, non prorietary and proprietary name K/S SH Y Lecture Written/ Viva voce
PH1.10 Describe parts of a correct, complete and legible generic prescription. Identify errors in prescription and correct appropriately K/S SH Y DOAP SKILL ASSESSMENT
Obj. 1 At the end of session a phase II student must be  able to describe parts of a prescription correctly K/S SH Y DOAP SKILL ASSESSMENT
Obj. 2 At the end of session a phase II student must be able to  enumerate essential components of an ideal prescription K/S SH Y DOAP SKILL ASSESSMENT
Obj. 3 At the end of session a phase II student must be  able to point out errors in a given sample prescription correctly   K/S SH Y DOAP SKILL ASSESSMENT
PH1.11 Describe various routes of drug administration, eg., oral, SC, IV, IM, SL K KH Y DOAP SKILL ASSESSMENT
Obj. 1 At the end of session a phase II student must be able to  ennumerate varoius routes of administration K KH Y DOAP SKILL ASSESSMENT
Obj. 2 At the end of session a phase II student must be  able to describe various routes of drug administration K KH Y DOAP SKILL ASSESSMENT
Obj. 3 At the end of session a phase II student must be  able to  enumerate advantages of various routes of drug administration K KH Y DOAP SKILL ASSESSMENT
Obj. 4 At the end of session a phase II student must be  able to  enumerate disadvantages of various routes of drug administration K KH Y DOAP SKILL ASSESSMENT
PH1.12 Calculate the dosage of drugs using appropriate formulae for an individual patient, including children, elderly and patient with renal dysfunction. K/S SH Y DOAP SKILL ASSESMENT Pediatrics, General
Medicine
Obj. 1 At the end of the session Phase II student must be able to write the formula to calculate drug dose according to body weight in a particular individual K K Y DOAP SKILL ASSESMENT
Obj. 2 At the end of the session Phase II student must be able to write the formula to calculate drug dose in children K K Y DOAP SKILL ASSESMENT
Obj. 3 At the end of the session Phase II student must be able to write the formula to calculate drug dose in elderly K K Y DOAP SKILL ASSESMENT
Obj. 4 At the end of the session Phase II student must be able to write the formula to calculate drug dose in patient with renal dysfunction K K Y DOAP SKILL ASSESMENT
Obj. 5 At the end of the session Phase II student must be able to calculate the drug dose according to body weight in a particular individual K/S KH Y DOAP SKILL ASSESMENT
Obj. 6 At the end of the session Phase II student must be able to calculate drug dose in elderly K/S KH Y DOAP SKILL ASSESMENT
Obj. 7 At the end of the session Phase II student must be able to calculate drug dose in children K/S KH Y DOAP SKILL ASSESMENT
Obj. 8 At the end of the session Phase II student must be able to calculate drug dose in patient with renal dysfunction K/S KH Y DOAP SKILL ASSESMENT
PH1.13 Describe mechanism of action, types, doses, side effects,indications and contraindications of adrenergic and anti-adrenergic drugs K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to define Adrenergic drugs K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to classify adrenergic drugs  K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to enumerate pharmacological actions of adrenergic drugs on different organ systems K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe pharmacological actions of adrenergic drugs on different organ systems K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate the adverse drug effects of adrenergic drugs  K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate the contraindications of adrenergic drugs  K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to enumerate the therapeutic uses of adrenergic drugs K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to define AntiAdrenergic drugs K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to classify antiadrenergic drugs  K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to enumerate pharmacological actions of antiadrenergic drugs on different organ systems K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe pharmacological actions of antiadrenergic drugs on different organ systems K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to enumerate the adverse drug effects of antiadrenergic drugs  K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to enumerate the contraindications of antiadrenergic drugs  K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to enumerate the therapeutic uses of antiadrenergic drugs K KH Y Lecture Written/ Viva voce
PH1.14 Describe mechanism of action, types, doses, side effects, indications and contraindications of cholinergic and anticholinergic drugs K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to define Cholinergic drugs K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to classify Cholinergic drugs  K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to enumerate pharmacological actions of Cholinergic drugs on different organ systems K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe pharmacological actions of Cholinergic drugs on different organ systems K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate the adverse drug effects of Cholinergic drugs  K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate the contraindications of Cholinergic drugs  K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to enumerate the therapeutic uses of Cholinergic drugs K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to define AntiCholinergic drugs K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to classify antiCholinergicdrugs  K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to enumerate pharmacological actions of antiCholinergicdrugs on different organ systems K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe pharmacological actions of antiCholinergic drugs on different organ systems K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to enumerate the adverse drug effects of antiCholinergic drugs  K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to enumerate the contraindications of antiCholinergicdrugs  K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to enumerate the therapeutic uses of antiCholinergic drugs K KH Y Lecture Written/ Viva voce
PH1.15 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of skeletal muscle relaxants K KH Y Lecture Written/ Viva voce Anesthesiology,
Physiology
Obj. 1 At the end of the session Phase II student must be able to define skeletal muscle relaxants K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to classify skeletal muscle relaxants K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe mechanism of action of peripherally acting muscle relaxants K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe mechanism of action of centrally acting muscle relaxants K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe mechanism of action of directly acting muscle relaxants K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate pharmacological actions of skeletal muscle relaxants K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to enumerate the adverse drug effects of skeletal muscle relaxants K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to enumerate the contraindications of skeletal muscle relaxants K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to enumerate the therapeutic uses of peripherally acting muscle relaxants K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to enumerate the therapeutic uses of centrally acting muscle relaxants K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to enumerate the therapeutic uses of directly acting muscle relaxants K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to describe the interaction between thiopentone sodium and succinylcholine K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to describe the interaction between general anesthetics and skeletal muscle relaxants K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to describe the interaction between aminoglycoside antibiotics and skeletal muscle relaxants K KH Y Lecture Written/ Viva voce
Obj, 15 At the end of the session Phase II student must be able to describe the interaction between anticholinesterases and skeletal muscle relaxants K KH Y Lecture Written/ Viva voce
PH1.16 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autacoids, including: anti-histaminics, 5-HT modulating drugs, NSAIDs, drugs for gout, anti-rheumatic drugs, drugs for migraine K KH Y Lecture Written/ Viva voce General Medicine
Obj. 1 At the end of the session Phase II student must be able to define Anti-histaminics K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to enumerate types of histaminic receptors K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe pharmacological actions of histamine according to specific receptor subtype K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to classify H1 receptor antagonists K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe mechanism of action of H1 receptor antagonists K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate therapeutic uses of  H1 receptor antagonists K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to enumerate adverse effects of  H1 receptor antagonists K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to enumerate contraindications of  H1 receptor antagonists K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to explain  drug interaction between CYP450 enzyme inhibitors and second generation H1 receptor antagonists K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to explain  drug interaction between TCA and H1 receptor antagonists K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe biosynthesis of serotonin (5-HT) K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to enumerate types of serotonin receptors K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to describe pharmacological actions of serotonin according to specific receptor subtype K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to enumerate 5-HT receptor agonists K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to enumerate 5-HT receptor antagonists K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of the session Phase II student must be able to enumerate therapeutic uses of 5-HT receptor agonists K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of the session Phase II student must be able to enumerate adverse effects of 5-HT receptor agonists K KH Y Lecture Written/ Viva voce
Obj. 18 At the end of the session Phase II student must be able to enumerate contraindications of  5-HT receptor agonists K KH Y Lecture Written/ Viva voce
Obj. 19 At the end of the session Phase II student must be able to enumerate therapeutic uses of 5-HT receptor antagonists K KH Y Lecture Written/ Viva voce
Obj. 20 At the end of the session Phase II student must be able to enumerate adverse effects of 5-HT receptor antagonists K KH Y Lecture Written/ Viva voce
Obj. 21 At the end of the session Phase II student must be able to enumerate contraindications of  5-HT receptor antagonists K KH Y Lecture Written/ Viva voce
Obj. 22 At the end of the session Phase II student must be able to enumerate drugs causing serotonin syndrome K KH Y Lecture Written/ Viva voce
Obj. 23 At the end of the session Phase II student must be able to enumerate types of Migraine K KH Y Lecture Written/ Viva voce
Obj. 24 At the end of the session Phase II student must be able to describe pathophysiology of Migraine K KH Y Lecture Written/ Viva voce
Obj. 25 At the end of the session Phase II student must be able to enumerate drugs used in treatment of acute migraine attack K KH Y Lecture Written/ Viva voce
Obj. 26 At the end of the session Phase II student must be able to enumerate drugs used in prophylaxis of migraine  K KH Y Lecture Written/ Viva voce
Obj. 27 At the end of the session Phase II student must be able to write a prescription for migraine  K KH Y small group discussion Written/ Viva voce
PH1.17 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of local anesthetics K KH Y Lecture Written/ Viva voce Anesthesiology
Obj. 1 At the end of the session Phase II student must be able to define local anesthetics  K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to classify local anesthetics  K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe mechanism of action of local anesthetics  K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to enumerate pharmacological actions of local anesthetics  K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate the adverse drug effects of local anesthetics  K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate the contraindications of local anesthetics  K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to enumerate the therapeutic uses of local anesthetics  K KH Y Lecture Written/ Viva voce
PH1.18 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of general anaesthetics, and preanesthetic medications K KH Y Lecture Written/ Viva voce Anesthesiology
Obj. 1 At the end of the session Phase II student must be able to define general anesthetics  K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to classify general anesthetics   K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe mechanism of action of general anesthetics   K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to enumerate pharmacological actions of general anesthetics   K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate the adverse drug effects of general anesthetics   K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate the contraindications of general anesthetics   K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to enumerate the therapeutic uses of general anesthetics   K KH Y Lecture Written/ Viva voce
PH1.19 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, antidepressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) K KH Y Lecture Written/ Viva voce Psychiatry,
Physiology
Obj. 1 At the end of the session Phase II student must be able to define Anxiety K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to classify AntiAnxiety drugs K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to  describe mechanism of action of antianxiety drugs  K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to enumerate the adverse drug effects of AntiAnxiety drugs K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate the contraindications of AntiAnxiety drugs   K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate other therapeutic uses of AntiAnxiety drugs   K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to write a prescription for situational anxiety K KH Y small group discussion Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to define sedatives K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to define hypnotics K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to classify drugs used for hypnosis K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to  describe mechanism of action of benzodiazepines as hypnotics  K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to  describe mechanism of action of nonbenzodiazepines as hypnotics  K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to enumerate the pharmacological effects of benzodiazepines  K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to enumerate the pharmacological effects of barbiturates K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to describe the pharmacological effects of barbiturates on CNS  K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of the session Phase II student must be able to enumerate the adverse drug effects of barbiturates K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of the session Phase II student must be able to enumerate the adverse drug effects of benzodiazepines K KH Y Lecture Written/ Viva voce
Obj. 18 At the end of the session Phase II student must be able to enumerate other therapeutic uses of barbiturates K KH Y Lecture Written/ Viva voce
Obj. 19 At the end of the session Phase II student must be able to enumerate other therapeutic uses of benzodiazepines K KH Y Lecture Written/ Viva voce
Obj. 20 At the end of the session Phase II student must be able to enumerate contraindications to the use of barbiturates K KH Y Lecture Written/ Viva voce
Obj. 21 At the end of the session Phase II student must be able to enumerate contraindications to the use of benzodiazepines K KH Y Lecture Written/ Viva voce
Obj. 22 At the end of the session Phase II student must be able to write a prescription for sleep onset insomnia K KH Y SGD Written/ Viva voce
Obj. 23 At the end of the session Phase II student must be able to write a prescription for jetlag/transient insomnia K KH Y SGD Written/ Viva voce
Obj. 24 At the end of the session Phase II student must be able to write a prescription for  benzodiazepine overdose K KH Y SGD Written/ Viva voce
Obj. 25 At the end of the session Phase II student must be able to explain  drug interaction between barbiturates and Oral contraceptives K KH Y Lecture Written/ Viva voce
Obj. 26 At the end of the session Phase II student must be able to explain  drug interaction between barbiturates and warfarin K KH Y Lecture Written/ Viva voce
Obj. 27 At the end of the session Phase II student must be able to explain  drug interaction between barbiturates and other CNS depressants K KH Y Lecture Written/ Viva voce
Obj. 28 At the end of the session Phase II student must be able to explain  drug interaction between benzodiazepines and sodium valproate K KH Y Lecture Written/ Viva voce
Obj. 29 At the end of the session Phase II student must be able to define Depression K KH Y Lecture Written/ Viva voce
Obj. 30 At the end of the session Phase II student must be able to enumerate types of depression K KH Y Lecture Written/ Viva voce
Obj. 31 At the end of the session Phase II student must be able to classify antidepressants on basis of their mechanism of action K KH Y Lecture Written/ Viva voce
Obj. 32 At the end of the session Phase II student must be able to  describe mechanism of action of atypical antidepressants K KH Y Lecture Written/ Viva voce
Obj. 33 At the end of the session Phase II student must be able to enumerate the pharmacological effects of TCA (Tricyclic Antidepressants) K KH Y Lecture Written/ Viva voce
Obj. 34 At the end of the session Phase II student must be able to describe pharmacokinetics of TCA K KH Y Lecture Written/ Viva voce
Obj. 35 At the end of the session Phase II student must be able to enumerate the adverse drug effects of TCAs K KH Y Lecture Written/ Viva voce
Obj. 36 At the end of the session Phase II student must be able to enumerate the contraindications of TCAs K KH Y Lecture Written/ Viva voce
Obj. 37 At the end of the session Phase II student must be able to enumerate the other therapeutic uses of TCAs K KH Y Lecture Written/ Viva voce
Obj. 38 At the end of the session Phase II student must be able to describe the mechanism of cheese reaction K KH Y Lecture Written/ Viva voce
Obj. 39 At the end of the session Phase II student must be able to describe the interaction between phenytoin and TCA K KH Y Lecture Written/ Viva voce
Obj. 40 At the end of the session Phase II student must be able to describe the interaction between SSRIs and TCA K KH Y Lecture Written/ Viva voce
Obj. 41 At the end of the session Phase II student must be able to explain the rationale of using SSRIs over TCA K KH Y Lecture Written/ Viva voce
Obj. 42 At the end of the session Phase II student must be able to explain the rationale of using SNRIs over TCA K KH Y Lecture Written/ Viva voce
Obj. 43 At the end of the session Phase II student must be able to enumerate other therapeutic uses of SSRIs  K KH Y Lecture Written/ Viva voce
Obj. 44 At the end of the session Phase II student must be able to write a prescription for depression K KH Y SGD Written/ Viva voce
PH1.20 Describe the effects of acute and chronic ethanol intake K KH Y SGD Written/ Viva voce Psychiatry
Obj. 1 At the end of the session Phase II student must be able to define acute ethanol intake correctly K KH Y SGD Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to define chronic ethanol intake correctly K KH Y SGD Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to define mild, moderate and severe consumption of ethanol correctly K KH Y SGD Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe the pharmacokinetic characteristics of ehanol correctly K KH Y SGD Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate the organs affected by acute ethanol intake correctly K KH Y SGD Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate the organs affected of chronic ethanol intake corrrectly K KH Y SGD Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe the effects of various quantities of ethanol consumption on liver correctly K KH Y SGD Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to describe the effects of various quantities of ethanol consumption on CNS correctly K KH Y SGD Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to describe the effects of various quantities of ethanol consumption on CVS correctly K KH Y SGD Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to describe the effects of various quantities of ethanol consumption during pregnancy correctly K KH Y SGD Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe tolerance and dependence to ethanol consumption correctly K KH Y SGD Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to enumerate the drugs having disulfiram like reaction with ethanol correctly K KH Y SGD Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to enumerate the drugs accentuating depressant effect of ethanol correctly K KH Y SGD Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to enumerate the drugs accentuating GIT symptoms of ethanol correctly K KH Y SGD Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to enumerate the drugs accentuating metabolic symptoms of ethanol correctly K KH Y SGD Written/ Viva voce
PH1.21 Describe the symptoms and management of methanol and ethanol poisonings
K KH Y SGD Written/ Viva voce General Medicine
Obj. 1 At the end of session Phase II student must be able to enumerate symptoms of methanol poisoning K KH Y SGD Written/ Viva voce
Obj. 2 At the end of session Phase II student must be able to enumerate symptoms of ethanol poisoning K KH Y SGD Written/ Viva voce
Obj. 3 At the end of session Phase II student must be able to write the prescription for methanol poisoning K KH Y SGD Written/ Viva voce
Obj. 4 At the end of session Phase II student must be able to write the prescription for ethanol poisoning K KH Y SGD Written/ Viva voce
Obj. 5 At the end of session Phase II student must be able to describe the rationale of drug used in methanol poisoning K KH Y SGD Written/ Viva voce
Obj. 6 At the end of session Phase II student must be able to describe the rationale of drug used in ethanol poisoning K KH Y SGD Written/ Viva voce
Obj. 7 At the end of session Phase II student must be able to enumerate the side effects of drugs used for methanol poisoning K KH Y SGD Written/ Viva voce
Obj. 8 At the end of session Phase II student must be able to enumerate  the side effects of drugs used for ethanol poisoning K KH Y SGD Written/ Viva voce
PH1.22 Describe drugs of abuse (dependence, addiction, stimulants, depressants, psychedelics, drugs used for criminal offences)
K KH Y Lecture Written/ Viva voce Psychiatry Forensic Medicine
Obj. 1 At the end of the session Phase II student must be able to define drugs of abuse  K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to  enumerate drugs of abuse K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to  classify drugs of abuse K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to define dependence correctly K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to define addiction correctly K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to define CNS stimulants correctly K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to define  CNS depressants correctly K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to define psychedelics correctly K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to define  drugs for criminal offences correctly K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to differentiate between dependence and addiction K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe tolerance  K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to describe  mechanism of withdrawl  K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to differentiate between dependence and addiction K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to define  CNS stimulants  K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to enumerate CNS stimulants K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of the session Phase II student must be able to define CNS depressants K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of the session Phase II student must be able to  enumerate CNS depressants K KH Y Lecture Written/ Viva voce
Obj. 18 At the end of the session Phase II student must be able to define  psychedelics  K KH Y Lecture Written/ Viva voce
Obj. 19 At the end of the session Phase II student must be able to enumerate psychedelics K KH Y Lecture Written/ Viva voce
Obj. 20 At the end of the session Phase II student must be able to define drugs for criminal offence K KH Y Lecture Written/ Viva voce
Obj. 21 At the end of the session Phase II student must be able to enumerate drugs for criminal offence K KH Y Lecture Written/ Viva voce
Obj. 23 At the end of the session Phase II student must be able to describe mechanism of action of  drugs of criminal offence  K KH Y Lecture Written/ Viva voce
PH1.23 Describe the process and mechanism of drug deaddiction K/S KH Y Lecture, Small group discussion Written/ Viva voce Psychiatry
Obj. 1 At the end of the session Phase II student must be able to define  drug deaddiction K/S KH Y Lecture, Small group discussion Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to  describe the process of drug deaddiction  K/S KH Y Lecture, Small group discussion Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to enumerate the drugs used for  drug deaddiction K/S KH Y Lecture, Small group discussion Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe mechanism of action of drugs for deaddiction K/S KH Y Lecture, Small group discussion Written/ Viva voce
PH1.24 Describe the mechanism/s of action, types, doses, side effects,
indications and contraindications of the drugs affecting renal
systems including diuretics, antidiuretics- vasopressin and
analogues
K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to define diuretics K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to define antidiuretics K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to classify diuretics K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe mechanism of action of  high ceiling/loop  diuretics K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe mechanism of action of thiazide  diuretics K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to describe mechanism of action of  potassium sparing diuretics K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe mechanism of action of  Osmotic diuretics K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to describe drug interaction between loop diuretics and potassium sparing diuretics K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to describe drug interaction between NSAIDs and Diuretics K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to describe drug interaction between Diuretics and Probenecid K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe drug interaction between loop diuretics and Aminoglycoside antibiotics K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to define antidiuretics K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to describe mechanism of action of Antidiuretic hormone K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to enumerate Vasopressin analogues K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to enumerate therapeutic uses of Vasopressin analogues K KH Y Lecture Written/ Viva voce
PH1.25 Describe the mechanism/s of action, types, doses, side effects,
indications and contraindications of the drugs acting on blood, like
anticoagulants, antiplatelets, fibrinolytics, plasma expanders
K KH Y Lecture Written/ Viva voce Physiology,
General Medicine
Obj. 1 At the end of the session Phase II student must be able to define Haematinics K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to describe pharmacokinetics of iron K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to enumerate factors affecting iron absorption K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe mucosal block K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to classify various preparations of iron K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to describe oral iron therapy K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe parenteral iron therapy K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to describe use of various iron preparations  K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to prescribe for iron deficiency anaemia  K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to describe acute iron poisoning K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe  pharmacokinetics of vitamin B12  K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to  enumerate uses of vitamin B12  K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to  prescribe for vitamin B12 deficiency anaemia  K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to describe  pharmacokinetics of Folic acid K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to  enumerate uses of folic acid K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of the session Phase II student must be able to describe  pharmacokinetics of erythropoetin K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of the session Phase II student must be able to describe use of erythropoetin K KH Y Lecture Written/ Viva voce
Obj. 18 At the end of the session Phase II student must be able to  enumerate the preparations of erythropoetin K KH Y Lecture Written/ Viva voce
Obj. 19 At the end of the session Phase II student must be able to define coagulants   K KH Y Lecture Written/ Viva voce
Obj. 20 At the end of the session Phase II student must be able to classify coagulants K KH Y Lecture Written/ Viva voce
Obj. 21 At the end of the session Phase II student must be able to describe the use of vitamin K  K KH Y Lecture Written/ Viva voce
Obj. 22 At the end of the session Phase II student must be able to define local haemostatics (stiptics) K KH Y Lecture Written/ Viva voce
Obj. 23 At the end of the session Phase II student must be able to enumerate styptics K KH Y Lecture Written/ Viva voce
Obj. 24 At the end of the session Phase II student must be able to describe the use of styptics K KH Y Lecture Written/ Viva voce
Obj. 25 At the end of the session Phase II student must be able to define anticoagulants K KH Y Lecture Written/ Viva voce
Obj. 26 At the end of the session Phase II student must be able to classify anticoagulants K KH Y Lecture Written/ Viva voce
Obj. 27 At the end of the session Phase II student must be able to describe the mechanism of action of heparin K KH Y Lecture Written/ Viva voce
Obj. 28 At the end of the session Phase II student must be able to describe pharmacological actions of heparin K KH Y Lecture Written/ Viva voce
Obj. 29 At the end of the session Phase II student must be able to describe pharmacokinetics of heparin K KH Y Lecture Written/ Viva voce
Obj. 30 At the end of the session Phase II student must be able to enumerate the adverse effects of heparin K KH Y Lecture Written/ Viva voce
Obj. 31 At the end of the session Phase II student must be able to enumerate contraindications of heparin use K KH Y Lecture Written/ Viva voce
Obj. 32 At the end of the session Phase II student must be able to enumerate uses of heparin K KH Y Lecture Written/ Viva voce
Obj. 33 At the end of the session Phase II student must be able to enumerate low molecular weight heparin K KH Y Lecture Written/ Viva voce
Obj. 34 At the end of the session Phase II student must be able to enumerate uses of low molecular weight heparin K KH Y Lecture Written/ Viva voce
Obj. 35 At the end of the session Phase II student must be able to differentiate between heparin and low molecular weight heparin K KH Y Lecture Written/ Viva voce
Obj. 36 At the end of the session Phase II student must be able to describe fondaparinux K KH Y Lecture Written/ Viva voce
Obj. 37 At the end of the session Phase II student must be able to enumerate heparin antagonists K KH Y Lecture Written/ Viva voce
Obj. 38 At the end of the session Phase II student must be able to enumerate direct parentral thrombin inhibitors K KH Y Lecture Written/ Viva voce
Obj. 39 At the end of the session Phase II student must be able to enumerate oral anticoagulants K KH Y Lecture Written/ Viva voce
Obj. 40 At the end of the session Phase II student must be able to describe the mechanism of action of warfarin K KH Y Lecture Written/ Viva voce
Obj. 41 At the end of the session Phase II student must be able to describe the pharmacokinetics of warfarin K KH Y Lecture Written/ Viva voce
Obj. 42 At the end of the session Phase II student must be able to enumerate indications of warfarin at various INR K KH Y Lecture Written/ Viva voce
Obj. 43 At the end of the session Phase II student must be able to enumerate adverse effects of warfarin K KH Y Lecture Written/ Viva voce
Obj. 44 At the end of the session Phase II student must be able to enumerate the factors enhancing the warfarin anticoagulant effect K KH Y Lecture Written/ Viva voce
Obj. 45 At the end of the session Phase II student must be able to enumerate the factors decreasing the warfarin anticoagulant effect K KH Y Lecture Written/ Viva voce
Obj. 46 At the end of the session Phase II student must be able to enumerate contraindications of warfarin K KH Y Lecture Written/ Viva voce
Obj. 47 At the end of the session Phase II student must be able to describe drug interaction between warfarin and cephalosporins K KH Y Lecture Written/ Viva voce
Obj. 48 At the end of the session Phase II student must be able to describe drug interactions of warfarin with salicylates K KH Y Lecture Written/ Viva voce
Obj. 49 At the end of the session Phase II student must be able to describe drug interactions of warfarin with sulphonamides K KH Y Lecture Written/ Viva voce
Obj. 50 At the end of the session Phase II student must be able to describe drug interactions of warfarin with phenytoin K KH Y Lecture Written/ Viva voce
Obj. 51 At the end of the session Phase II student must be able to describe drug interactions of warfarin with barbiturates K KH Y Lecture Written/ Viva voce
Obj. 52 At the end of the session Phase II student must be able to describe drug interactions of warfarin with oral contraceptives K KH Y Lecture Written/ Viva voce
Obj. 53 At the end of the session Phase II student must be able to enumerate direct factor Xa inhibitors K KH Y Lecture Written/ Viva voce
Obj. 54 At the end of the session Phase II student must be able to describe the mechanism of action of direct factor Xa inhibitors K KH Y Lecture Written/ Viva voce
Obj. 55 At the end of the session Phase II student must be able to enumerate uses of direct factor Xa inhibitors K KH Y Lecture Written/ Viva voce
Obj. 56 At the end of the session Phase II student must be able to enumerate oral direct thrombin inhibitors K KH Y Lecture Written/ Viva voce
Obj. 57 At the end of the session Phase II student must be able to describe the mechanism of action of direct thrombin inhibitors K KH Y Lecture Written/ Viva voce
Obj. 58 At the end of the session Phase II student must be able to describe advantages of new oral anticoagulants over warfarin K KH Y Lecture Written/ Viva voce
Obj. 59 At the end of the session Phase II student must be able to describe choice of anticoagulant for various clinical conditions K KH Y Lecture Written/ Viva voce
Obj. 60 At the end of the session Phase II student must be able to define antiplatlet drugs K KH Y Lecture Written/ Viva voce
Obj. 61 At the end of the session Phase II student must be able to classify antiplatlet drugs on the basis of mechanism of action K KH Y Lecture Written/ Viva voce
Obj. 62 At the end of the session Phase II student must be able to enumerate uses of antiplatlet drugs K KH Y Lecture Written/ Viva voce
Obj. 63 At the end of the session Phase II student must be able to define fibrinolytics  K KH Y Lecture Written/ Viva voce
Obj. 64 At the end of the session Phase II student must be able to enumerate fibrinolytic drugs K KH Y Lecture Written/ Viva voce
Obj. 65 At the end of the session Phase II student must be able to enumerate uses of fibrinolytic drugs K KH Y Lecture Written/ Viva voce
Obj. 66 At the end of the session Phase II student must be able to enumerate contraindications of thrombolytic therapy K KH Y Lecture Written/ Viva voce
Obj. 67 At the end of the session Phase II student must be able to define antifibrinolytic drugs K KH Y Lecture Written/ Viva voce
Obj. 68 At the end of the session Phase II student must be able to enumerate antifibrinolytic drugs K KH Y Lecture Written/ Viva voce
Obj. 69 At the end of the session Phase II student must be able to enumerate uses of antifibrinolytic drugs K KH Y Lecture Written/ Viva voce
Obj. 70 At the end of the session Phase II student must be able to define plasma expanders K KH Y Lecture Written/ Viva voce
Obj. 71 At the end of the session Phase II student must be able to enumerate plasma expanders K KH Y Lecture Written/ Viva voce
PH1.26 Describe mechanisms of action, types, doses, side effects,
indications and contraindications of the drugs modulating the reninangiotensin
and aldosterone system
K KH Y Lecture Written/ Viva voce Physiology,
General Medicine
Obj. 1 At the end of the session Phase II student must be able to define RAAS K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to describe pathophysiology of RAAS K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to enumerate pharmacological actions of RAAS K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to enumerate pathophysiological roles of RAAS K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate drugs affecting RAAS K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to define ACE inhibitors K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to enumerate ACE inhibitors K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to describe mechanism of action of ACE inhibitors K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to describe pharmacokinetics of ACE inhibitors K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to enumerate uses of ACE inhibitors K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe adverse effects of ACE inhibitors K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to describe the interactions of diuretics with ACE inhibitors K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to describe the interactions of NSAIDs with ACE inhibitors K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to describe the interactions of potassium sparing diuretics with ACE inhibitors K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to define angiotensin receptor blockers K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of the session Phase II student must be able to describe the mechanism of action of ARBs K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of the session Phase II student must be able to describe pharmacokinetics of ARBs K KH Y Lecture Written/ Viva voce
Obj. 18 At the end of the session Phase II student must be able to enumerate uses of ARBs K KH Y Lecture Written/ Viva voce
Obj. 19 At the end of the session Phase II student must be able to enumerate side effects of ARBs K KH Y Lecture Written/ Viva voce
Obj. 20 At the end of the session Phase II student must be able to enumerate direct renin inhibitors K KH Y Lecture Written/ Viva voce
Obj. 21 At the end of the session Phase II student must be able to describe the mechanism of action of direct renin inhibitors K KH Y Lecture Written/ Viva voce
Obj. 22 At the end of the session Phase II student must be able to enumerate the adverse effects of direct renin inhibitors K KH Y Lecture Written/ Viva voce
PH1.27 Describe the mechanisms of action, types, doses, side effects,
indications and contraindications of antihypertensive drugs and
drugs used in shock
K KH Y Lecture Written/ Viva voce General Medicine
Obj. 1 At the end of the session Phase II student must be able to define hypertension K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to classify hypertension K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to define antihypertensives correctly  K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to classify antihypertensives  K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe mechanism of action of various antihypertensives  K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to describe  rationale of use of beta blockers in hypertension  K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe  rationale of use of diuretics in hypertension  K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to describe  rationale of use of Angiotensin converting enzyme inhibitors  in hypertension  K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to describe  rationale of use of calcium channel blockers in hypertension  K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to describe  rationale of use of methyl dopa in hypertension  K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe rationale of use of sodium nitroprusside in hypertension K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to define pregnancy induced hypertension K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to enumerate drugs for hypertension in pregnancy K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to define hypertensive emergency K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to define hypertensive urgency K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of the session Phase II student must be able to enumerate drugs for hypertensive emergency K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of the session Phase II student must be able to write a prescription for essential hypertension K KH Y SGD Written/ Viva voce
Obj. 18 At the end of the session Phase II student must be able to write a prescription for pregnancy induced hypertension K KH Y SGD Written/ Viva voce
Obj. 19 At the end of the session Phase II student must be able to write a prescription for hypertensive emergency K KH Y SGD Written/ Viva voce
Obj. 20 At the end of the session Phase II student must be able to enumerate various types of shock K KH Y Lecture Written/ Viva voce
Obj. 21 At the end of the session Phase II student must be able to describe the management for various types of shock K KH Y Lecture Written/ Viva voce
PH1.28 Describe the mechanisms of action, types, doses, side effects,
indications and contraindications of the drugs used in
ischemic heart disease (stable, unstable angina and myocardial
infarction), peripheral vascular disease
K KH Y Lecture Written/ Viva voce General Medicine
Obj. 1 At the end of the session Phase II student must be able to define stable angina K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to define unstable angina K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to define vasospastic angina K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe pathophysiology of angina K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to define antianginal drugs K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to classify antianginal drugs K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe mechanim of action of nitrates K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to describe the pharmacokinetics of nitrates K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to describe tolerance with nitrates K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to describe the side effects of nitrates K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe the uses of nitrates K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to enumerate the routes of administration for nitrates K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to describe the interactions of nitrates with phosphodiesterase 5 inhibitors K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to classify calcium channel blockers K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to describe the mechanism of action of calcium channel blockers K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of the session Phase II student must be able to describe the pharmacological actions of various calcium channel blockers K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of the session Phase II student must be able to describe the pharmacokinetics of calcium channel blockers K KH Y Lecture Written/ Viva voce
Obj. 18 At the end of the session Phase II student must be able to enumerate the uses of calcium channel blockers K KH Y Lecture Written/ Viva voce
Obj. 19 At the end of the session Phase II student must be able to enumerate the side effects of calcium channel blockers K KH Y Lecture Written/ Viva voce
Obj. 20 At the end of the session Phase II student must be able to enumerate potassium channel operners K KH Y Lecture Written/ Viva voce
Obj. 21 At the end of the session Phase II student must be able to enumerate newer antianginal drugs K KH Y Lecture Written/ Viva voce
Obj. 22 At the end of the session Phase II student must be able to describe mechanism of action of ranolazine K KH Y Lecture Written/ Viva voce
Obj. 23 At the end of the session Phase II student must be able to describe the mechanism of action of ivabradine K KH Y Lecture Written/ Viva voce
Obj. 24 At the end of the session Phase II student must be able to describe the mechanism of action of trimetazidine K KH Y Lecture Written/ Viva voce
Obj. 25 At the end of the session Phase II student must be able to describe the coronary steal phenomenon with dipyridamole K KH Y Lecture Written/ Viva voce
Obj. 26 At the end of the session Phase II student must be able to prescribe for stable angina K KH Y SGD Written/ Viva voce
Obj. 27 At the end of the session Phase II student must be able to describe the rationale of drugs used  K KH Y Lecture Written/ Viva voce
Obj. 28 At the end of the session Phase II student must be able to prescribe for unstable angina K KH Y SGD Written/ Viva voce
Obj. 29 At the end of the session Phase II student must be able to describe the rationale for drugs used K KH Y Lecture Written/ Viva voce
Obj. 30 At the end of the session Phase II student must be able to must be able to define myocardial infarction K KH Y Lecture Written/ Viva voce
Obj. 31 At the end of the session Phase II student must be able to must be able to enumerate the drugs used in myocardial infarction K KH Y Lecture Written/ Viva voce
Obj. 32 At the end of the session Phase II student must be able to must be able to prescribe for myocardial infarction K KH Y SGD Written/ Viva voce
Obj. 33 At the end of the session Phase II student must be able to describe the rationale for drugs used K KH Y Lecture Written/ Viva voce
Obj. 34 At the end of the session Phase II student must be able to define peripheral vascular disease K KH Y Lecture Written/ Viva voce
Obj. 35 At the end of the session Phase II student must be able to classify drugs used in peripheral vascular disease K KH Y Lecture Written/ Viva voce
PH1.29 Describe the mechanisms of action, types, doses, side effects,
indications and contraindications of the drugs used in
congestive heart failure
K KH Y Lecture Written/ Viva voce General Medicine
Obj. 1 At the end of the session Phase II student must be able to define congestive heart failure K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to describe the pathophysiology of congestive heart failure K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to classify drugs for congestive heart failure K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe the mechanism of action of digoxin K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe the pharmacological actions of digoxin on heart K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to to describe the pharmacokinetics of digoxin K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to enumerate the side effects of digoxin K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to enumerate contraindications of digoxin K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to describe digoxin toxicity K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to enumerate uses of digoxin K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe the interaction of diuretics with digoxin K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to describe the rationale of diuretics in CHF K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to describe the rationale of vasodilators in CHF K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to describe the rationale of aldosterone antagonist in CHF K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to describe the rationale of ACE inhibitors in CHF K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of the session Phase II student must be able to enumerate cardioselective beta blockers in CHF K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of the session Phase II student must be able to  describe the rationale of cardioselective beta blockers in CHF K KH Y Lecture Written/ Viva voce
Obj. 18 At the end of the session Phase II student must be able to enumerate newer drugs used in CHF K KH Y Lecture Written/ Viva voce
Obj. 19 At the end of the session Phase II student must be able to must be able to prescribe for  chronic heart failure K KH Y SGD Written/ Viva voce
Obj. 20 At the end of the session Phase II student must be able to must be able to describe rationale of drugs used K KH Y SGD Written/ Viva voce
Obj. 21 At the end of the session Phase II student must be able to must be able to prescribe for  decompensated  heart failure K KH Y SGD Written/ Viva voce
Obj. 22 At the end of the session Phase II student must be able to must be able to describe rationale of drugs used K KH Y SGD Written/ Viva voce
PH1.30 Describe the mechanisms of action, types, doses, side effects,
indications and contraindications of the antiarrhythmics
K KH N Lecture Written/ Viva voce General Medicine
Obj. 1 At the end of the session Phase II student must be able to describe cardiac electrophysiology K KH N Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to define cardiac arrythmias K KH N Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe different types of cardiac arrythmias K KH N Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to classify antiarrythmic drugs K KH N Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe the mechanism of action of class I antiarrythmic drugs K KH N Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate uses of class I antiarrythmic drugs K KH N Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe the mechanism of action of class II antiarrythmic drugs K KH N Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to enumerate uses of class II antiarrythmic drugs K KH N Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to describe the mechanism of action of class III antiarrythmic drugs K KH N Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to enumerate the uses of class III antiarrythmic drugs K KH N Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe the mechanism of action of amiodarone K KH N Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to enumerate the adverse effects of amiodarone K KH N Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to describe the mechanism of action of class IV antiarrythmic drugs K KH N Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to enumerate the uses of class IV antiarrythmic drugs K KH N Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to enumerate drugs for paroxysmal supraventricular tachycardia K KH N Lecture Written/ Viva voce
Obj. 16 At the end of the session Phase II student must be able to describe the mechanism of action of adenosine K KH N Lecture Written/ Viva voce
Obj. 17 At the end of the session Phase II student must be able to enumerate uses of adenosine K KH N Lecture Written/ Viva voce
Obj. 18 At the end of the session Phase II student must be able to enumerate drugs for sinus tachycardia K KH N Lecture Written/ Viva voce
Obj. 19 At the end of the session Phase II student must be able to enuerate drugs for AV block K KH N Lecture Written/ Viva voce
Obj. 20 At the end of the session Phase II student must be able to write a prescription for paroxysmal supraventricular tachcardia K KH N SGD Written/ Viva voce
Obj. 21 At the end of the session Phase II student must be able to write a prescription for atrial fibrillation K KH N SGD Written/ Viva voce
Obj. 22 At the end of the session Phase II student must be able to write a prescription for atrial flutter K KH N SGD Written/ Viva voce
Obj. 23 At the end of the session Phase II student must be able to write a prescription for AV block K KH N SGD Written/ Viva voce
Obj. 24 At the end of the session Phase II student must be able to write a prescription for bradycardia K KH N SGD Written/ Viva voce
PH1.31 Describe the mechanisms of action, types, doses, side effects,
indications and contraindications of the drugs used in the
management of dyslipidemias
K KH Y Lecture Written/ Viva voce General Medicine
Obj. 1 At the end of the session Phase II student must be able to define dyslipidaemia K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to enumerate the various drugs used in the management of dyslipidaemia K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe the mechanism of action of statins, Fibrates and niacin K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to enumerate the indications of statins K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate the contraindications of statins K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate the specific side effects of statins K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to differentiate the difference b/w statins and fibrates K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to identify the right drug based on lipid profile analysis K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to write a prescription for dyslipidaemia K KH Y SGD Written/ Viva voce
PH1.32 Describe the mechanism/s of action, types, doses, side effects,
indications and contraindications of drugs used in bronchial asthma
and COPD
K KH Y Lecture Written/ Viva voce Respiratory Medicine
Obj. 1 At the end of the session Phase II student must be able to enumerate the drugs used in the treatment of acute attack of bronchial asthma K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to enumerate the drugs used for prophtlaxis in bronchial asthma K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe the management of status asthmaticus K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to enumerate the differences b/w short acting and long acting beta2 agonists K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate the adverse effects of inhaled corticosteroids K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to describe the mechanism of action of beta2 agonist, methylxanthines, anticholinergics and glucocorticoids in bronchial asthma K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe the management of asthma during pregnancy and lactation K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to describe the role of leukotrine inhibitors in asthma K KH Y Lecture Written/ Viva voce
PH1.33 Describe the mechanism of action, types, doses, side effects,
indications and contraindications of the drugs used in cough
(antitussives, expectorants/ mucolytics)
K KH Y Lecture Written/ Viva voce Respiratory Medicine
Obj. 1 At the end of the session Phase II student must be able to enumerate the drugs used as antitussives K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to enumerate the differences b/w expectorants and mucolylics K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe the role of antihistamine in cough K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to give comments on various cough mixtures and FDC K KH Y Lecture Written/ Viva voce
PH1.34 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs used as below:
1. Acid-peptic disease and GERD
2. Antiemetics and prokinetics
3. Antidiarrhoeals
4 . Laxatives
5. Inflammatory Bowel Disease
6. Irritable Bowel Disorders, biliary and pancreatic diseases
K KH Y Lecture Written/ Viva voce General Medicine
Obj. 1 At the end of the session Phase II student must be able to enumerate the various drugs used in the management of PUD K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to describe the mechanism of action of PPIs K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to give comments on different regimens for H.pylori induced peptic ulcer K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to give comments on management of NSAIDs induced peptic ulcer K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate the drugs used in the treatment of constipation K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate the difference b/w osmotic laxative and bulk forming laxative K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe the mechanism of action of lactulose in constipation K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to enumerate the various drugs used in the management of diarrhoea K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to describe the role of prebiotics and probiotics in the management of diarrhoea K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to describe the role of antimicrobial agents in the management of diarrhoea K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to enumerate the drugs used in the treatment of IBD K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to enumerate the drugs used in the treatment of Irritable bowel syndrome K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to define prokinetic drugs with e.g. K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to enumerate the drugs used as antiemetic therapy K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to describe the mechanism of action of 5-HT3 antagonist as antiemetic action K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of the session Phase II student must be able to describe the mechanism of action of 5-HT4 agonist as prokinetic action K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of the session Phase II student must be able to describe the drugs used in the management of CRINV K KH Y Lecture Written/ Viva voce
Obj. 18 At the end of the session Phase II student must be able to enumeratethe drugs used in the management of vertigo K KH Y Lecture Written/ Viva voce
Obj. 19 At the end of the session Phase II student must be able to enumerate the drugs used in the management of motion sickness K KH Y Lecture Written/ Viva voce
K KH Y Lecture Written/ Viva voce
PH1.35 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of drugs used in hematological
disorders like:
1. Drugs used in anemias
2. Colony Stimulating factors
K KH Y Lecture Written/ Viva voce General Medicine,
Physiology
Pharmacology
Obj. 1 At the end of the session Phase II student must be able to define the different types of nutritional deficiency anaemia K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to enumerate the various types of oral iron salts available for the treatment of iron deficiency anaemia K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to enumerate the various types of parenteral iron salts available for the treatment of iron deficiency anaemia K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to differentiate the difference b/w iron dextran and iron sorbitol K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe the management of chronic iron toxicity K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate the various forms of commercially available vitamin B12 K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describes the management of pernicious anaemia K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to describe the management of nutritional megaloblastic anaemia K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to describes the management of drug-induced megaloblastic anaemia K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to describes the management of anaemia in CRF K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describes the management of drug-induced neutropenia K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to calculate the dose of iron dextran for IV route by using appropriate formula in different clinical scenario K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to demonstrate the technique for IM injection of iron sorbitol K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to identify the right drug for the treatment of anaemia based on CBC analysis report K KH Y SGD Written/ Viva voce
PH1.36 Describe the mechanism of action, types, doses, side effects,
indications and contraindications of drugs used in endocrine
disorders (diabetes mellitus, thyroid disorders and osteoporosis)
K KH Y Lecture Written/ Viva voce General Medicine
Obj. 1 At the end of the session Phase II student must be able to give comment on thyroid replacement therapy on various types of hypothyroidism K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to enumerate the various antithyroid drugs K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe the mechanism of action of antithyroid drugs K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe the management of thyroid storm K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe the management of thyrotoxicosis during pregnancy and lactation K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to describe the mechanism of action and role of iodine in thyroid disorders K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe the mechanism of action, role and disadvantages of radioactive iodine in hyperthyroidism K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to describe the role of beta blockers in hyperthyroidism K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to define somogyi phenomenon  K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to describe the various insulin analogues K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to enumerate the difference b/w animal and human insulin K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to describe insulin resistance and its management K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to demonstrate the various method for the insulin delivery  K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to give comment on the onset and duration of action of human insulin, inhaled insulin and insulin analogues by drawing a graph K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to enumerate the various oral antidiabetic drugs K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of the session Phase II student must be able to describe the mechanism of action and adverse effects of sulphonylureas K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of the session Phase II student must be able to describe the role of incretinmimetics in the management of NIDDM. K KH Y Lecture Written/ Viva voce
Obj. 18 At the end of the session Phase II student must be able to describe the role of insulin sensitizers in the management of NIDDM. K KH Y Lecture Written/ Viva voce
Obj. 19 At the end of the session Phase II student must be able to calculate the dose of insulin for a day in different clinical scenarios K KH Y Lecture Written/ Viva voce
Obj. 20 At the end of the session Phase II student must be able to enumerate the drugs used in the treatment of diabetic neuropathy K KH Y Lecture Written/ Viva voce
Obj. 21 At the end of the session Phase II student must be able to describe the management of diabetic ketoacidosis K KH Y Lecture Written/ Viva voce
Obj. 22 At the end of the session Phase II student must be able to describe the management of hyperglycaemic hyperosmolar coma K KH Y Lecture Written/ Viva voce
Obj. 23 At the end of the session Phase II student must be able to enumerate the drugs used in the management of osteoporosis K KH Y Lecture Written/ Viva voce
PH1.37 Describe the mechanisms of action, types, doses, side effects,
indications and contraindications of the drugs used as sex
hormones, their analogues and anterior Pituitary hormones
K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to define anabolic steroids K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to give comments on the use and misuse of anabolic steroids K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe the role of androgen receptor blockers in prostate cancer K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to enumerate the drugs used in the treatment of BPH K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate the drugs used in the treatment of male erectile dysfunction K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to comment on the precautions and contraindications for the use of PDE-5 inhibitors K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to comment on the uses, precautions and contraindications for the use of HRT in postmenopausal women K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to enumerate the SERM and its clinical uses K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to describe the effect of tamoxifen and raloxifen on various tissues K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to describe the role of clomiphene citrate in the management of female infertility K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to describe the aromatase inhibitors and it uses in clinical practice K KH Y Lecture Written/ Viva voce
Obj. 12 At the end of the session Phase II student must be able to describe the synthetic progestins and their clinical uses K KH Y Lecture Written/ Viva voce
Obj. 13 At the end of the session Phase II student must be able to describe the role of mifepristone in 1st trimester abortion K KH Y Lecture Written/ Viva voce
Obj. 14 At the end of the session Phase II student must be able to comment on the drugs use for postcoital contraception K KH Y Lecture Written/ Viva voce
Obj. 15 At the end of the session Phase II student must be able to describe the mechanism of action of combined pills K KH Y Lecture Written/ Viva voce
Obj. 16 At the end of the session Phase II student must be able to describe the role of monophasic pills in contraception K KH Y Lecture Written/ Viva voce
Obj. 17 At the end of the session Phase II student must be able to discuss the parenteral contraception and its adverse effects K KH Y Lecture Written/ Viva voce
Obj. 18 At the end of the session Phase II student must be able to comment on the norplant K KH Y Lecture Written/ Viva voce
Obj. 19 At the end of the session Phase II student must be able to describe the adverse effects and contraindications of combined pills K KH Y Lecture Written/ Viva voce
Obj. 20 At the end of the session Phase II student must be able to comment on the non-contraceptive benefits of oral pills K KH Y Lecture Written/ Viva voce
Obj. 21 At the end of the session Phase II student must be able to comment on the guidelines and precautions for using oral contraceptives K KH Y Lecture Written/ Viva voce
Obj. 22 At the end of the session Phase II student must be able to enumerate the drugs used in the treatment of acromegaly K KH Y Lecture Written/ Viva voce
Obj. 23 At the end of the session Phase II student must be able to enumerate the GnRH analogues and their route of administration K KH Y Lecture Written/ Viva voce
Obj. 24 At the end of the session Phase II student must be able to describe the clinical uses of GnRH analogues K KH Y Lecture Written/ Viva voce
Obj. 25 At the end of the session Phase II student must be able to describe the GnRH antagonists and their clinical uses K KH Y Lecture Written/ Viva voce
PH1.38 Describe the mechanism of action, types, doses, side effects,
indications and contraindications of corticosteroids
K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to comment on the guidelines followed for the use of corticosteroids K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to comment on the management of HPA-axis suppression K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe the clinical uses of corticosteroids K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe the adverse effects of corticosteroids K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe the contraindications of corticosteroids K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to describe the role of inhaled steroids in internal medicine K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe the role of topical steroids in dermatology K KH Y Lecture Written/ Viva voce
PH1.39 Describe mechanism of action, types, doses, side effects,
indications and contraindications the drugs used for contraception
K KH Y Lecture Written/ Viva voce Obstetrics &
Gynaecology
Obj. 1 At the end of the session Phase II student must be able to define contraception K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to enumerate the  types of contraception  K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to enumerate types of oral contraceptive pills K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to  enumerate the types of injectable contraceptives K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe mechanism of action of hormonal contraceptives K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate side effects of hormonal contraceptives K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to enumerate contraindications  of hormonal contraceptives K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to describe interactions of contraceptives with enzyme inducers K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to identify the choice of contraceptive for a particular individual  K KH Y SGD Written/ Viva voce
PH1.40 Describe mechanism of action, types, doses, side effects, indications and contraindications of
1. Drugs used in the treatment of infertility, and
2. Drugs used in erectile dysfunction
K KH Y Lecture Written/ Viva voce Obstetrics &
Gynaecology
Obj. 1 At the end of session phase II student must be able to describe the  mechanism of actions of drugs used in the treatment of infertility and  in erectile dysfunction K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of session phase II student must be able to classify the drugs used in the treatment of infertility and in erectile dysfunction K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of session phase II student must be able to describe the doses of drugs used in the treatment of infertility and  in erectile dysfunction K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of session phase II student must be able to describe the side effects of the drugs used in the treatment of infertility and in erectile dysfunction  K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of session phase II student must be able to describe the indications of the drugs used in the treatment of infertility and in erectile dysfunction K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of session phase II student must be able to describe the contraindications of the drugs used in the treatment of infertility and in erectile dysfunction K KH Y Lecture Written/ Viva voce
PH1.41 Describe the mechanisms of action, types, doses, side effects,
indications and contraindications of uterine relaxants and
stimulants
K KH Y Lecture Written/ Viva voce Obstetrics &
Gynaecology
Obj. 1 At the end of session phase II student must be able to describe the  mechanism of actions of of uterine relaxants and stimulants K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of session phase II student must be able to classify the drugs used as uterine relaxants and stimulants K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of session phase II student must be able to describe the doses of drugs used as uterine relaxants and stimulants K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of session phase II student must be able to describe the side effects of drugs used as uterine relaxants and stimulants K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of session phase II student must be able to describe the indications of drugs used as uterine relaxants and stimulants K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of session phase II student must be able to describe the contraindications of drugs used as uterine relaxants and stimulants K KH Y Lecture Written/ Viva voce
PH1.42 Describe general principles of chemotherapy K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of session phase II student must be able to classify type of organism against which primarily active K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of session phase II student must be able to differentiate the spectrum of activity of antimicrobials K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of session phase II student must be able to describe the type of actions i.e primarily bacteriostatic or bacteriocidal K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of session phase II student must be able to describe natural source of antibiotics K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of session phase II student must be able to discuss choice of antimicrobial on the basis of patient factors, drug factors K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of session phase II student must be able to demonsrate choice of antimicrobial on the basis of  organism related K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of session phase II student must be able to discuss Rationale for combined use of medicines K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of session phase II student must be able to describe mechanism of drug resistances, type , clinical relevance K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of session phase II student must be able to describe hypersensitivity, superinfections, toxicity K KH Y Lecture Written/ Viva voce
PH1.43 Describe and discuss the rational use of antimicrobials including
antibiotic stewardship program
K KH Y SGD Written/ Viva voce General Medicine,
Pediatrics
Microbiology
Obj. 1 At the end of session phase II student must be able to describe rational use of antibiotics in hospital to counteract antimicrobial resistance outcomes  K KH Y SGD Written/ Viva voce
Obj. 2 At the end of session phase II student must be able to describe steps to improve the quality of care of patients with infections by maximising clinical outcomes K KH Y SGD Written/ Viva voce
Obj. 3 At the end of session phase II student must be able to describe the steps to minimise toxicity K KH Y SGD Written/ Viva voce
PH1.44 Describe the first line antitubercular dugs, their mechanisms of
action, side effects and doses.
K KH Y Lecture Written/ Viva voce Respiratory Medicine
Obj. 1 At the end of session phase II student must be able to enumerate the first line antitubercular drugs K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of session phase II student must be able to describe the mechanism of action of first line antitubercular drugs K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of session phase II student must be able to describe the side effects of first line antitubercular drugs K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of session phase II student must be able to describe the doses of first line antitubercular drugs K KH Y Lecture Written/ Viva voce
PH1.45 Describe the dugs used in MDR and XDR Tuberculosis K KH Y Lecture Written/ Viva voce Respiratory Medicine Microbiology
Obj. 1 At the end of session phase II student must be able to enumerate the drugs used in MDR Tuberculosis K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of session phase II student must be able to enumerate the  drugs used in XDR Tuberculosis K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of session phase II student must be able to describe the mechanism of drugs used in MDR  and Tuberculosis K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of session phase II student must be able to describe the side effects of  drugs used in MDR and XDR Tuberculosis K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of session phase II student must be able to describe the indications of  drugs used in MDR and XDR Tuberculosis K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of session phase II student must be able to describe the contraindications of  drugs used in MDR and XDR Tuberculosis K KH Y Lecture Written/ Viva voce
PH1.46 Describe the mechanisms of action, types, doses, side effects,
indications and contraindications of antileprotic drugs
K KH Y Lecture Written/ Viva voce Dermatology,
Venereology &
Leprosy
Microbiology
Obj. 1 At the end of session phase II student must be able to classify the antileprotic drugs K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of session phase II student must be able to describe the mechanism of action of the antileprotic drugs K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of session phase II student must be able to describe the side effects of the antileprotic drugs K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of session phase II student must be able to describe the indications of the antileprotic drugs K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of session phase II student must be able to describe the contraindications of  theantileprotic drugs K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of session phase II student must be able to able to describe the doses of the antileprotic drugs K KH Y Lecture Written/ Viva voce
PH1.47 Describe the mechanisms of action, types, doses, side effects,
indications and contraindications of the drugs used in malaria,
KALA-AZAR, amebiasis and intestinal helminthiasis
K KH Y Lecture, SGD Written/ Viva voce General Medicine Microbiology
Obj. 1 At the end of session phase II student must be able to classify the drugs used in malaria K KH Y Lecture, SGD Written/ Viva voce
Obj. 2 At the end of session phase II student must be able to classify the drugs used in KALA-AZAR K KH Y Lecture, SGD Written/ Viva voce
Obj. 3 At the end of session phase II student must be able to classify the drugs used in Amoebiasis  K KH Y Lecture, SGD Written/ Viva voce
Obj. 4 At the end of session phase II student must be able to classify the drugs used in intestinal helminthiasis K KH Y Lecture, SGD Written/ Viva voce
Obj. 5 At the end of session phase II student must be able to describe the mechanism of drugs used in malaria K KH Y Lecture, SGD Written/ Viva voce
Obj. 6 At the end of session phase II student must be able to describe the mechanism of drugs used in KALA-AZAR K KH Y Lecture, SGD Written/ Viva voce
Obj. 7 At the end of session phase II student must be able to describe the mechanism of drugs used in Amoebiasis  K KH Y Lecture, SGD Written/ Viva voce
Obj. 8 At the end of session phase II student must be able to describe the  mechanism of drugs used in intestinal helminthiasis K KH Y Lecture, SGD Written/ Viva voce
Obj. 9 At the end of session phase II student must be able to enumerate the ADRs of the drugs used in malaria K KH Y Lecture, SGD Written/ Viva voce
Obj. 10 At the end of session phase II student must be able to enumerate the ADRs of the drugs used in KALA-AZAR, K KH Y Lecture, SGD Written/ Viva voce
Obj. 11 At the end of session phase II student must be able to enumerate the ADRs of the drugs used in Amoebiasis  K KH Y Lecture, SGD Written/ Viva voce
Obj. 12 At the end of session phase II student must be able to enumerate the ADRs of the drugs used in intestinal helminthiasis K KH Y Lecture, SGD Written/ Viva voce
Obj. 13 At the end of session phase II student must be able to enumerate the indications of the drugs used in malaria K KH Y Lecture, SGD Written/ Viva voce
Obj. 14 At the end of session phase II student must be able to enumerate the indications of the drugs used in KALA-AZAR K KH Y Lecture, SGD Written/ Viva voce
Obj. 15 At the end of session phase II student must be able to enumerate the indications of the drugs used in Amoebiasis  K KH Y Lecture, SGD Written/ Viva voce
Obj. 16 At the end of session phase II student must be able to enumerate the indications of the drugs used in intestinal helminthiasis K KH Y Lecture, SGD Written/ Viva voce
PH1.48 Describe the mechanisms of action, types, doses, side effects,
indications and contraindications of the drugs used in UTI/ STD
and viral diseases including HIV
K KH Y Lecture, SGD Written/Viva voce Microbiology
Obj. 1 At the end of session phase II student must be able to describe the mechanism ofthe drugs used in UTI/STD and viral disease including HIV K KH Y Lecture, SGD Written/Viva voce
Obj. 2 At the end of session phase II student must be able to classify the drugs  used in UTI/STD and viral disease including HIV K KH Y Lecture, SGD Written/Viva voce
Obj. 3 At the end of session phase II student must be able to describe the doses of the drugs used in UTI/STD and viral disease including HIV K KH Y Lecture, SGD Written/Viva voce
Obj. 4 At the end of session phase II student must be able to describe the side effects of the drugs used in UTI/STD and viral disease including HIV K KH Y Lecture, SGD Written/Viva voce
Obj. 5 At the end of session phase II student must be able to describe the indications of the drugs used in UTI/STD and viral disease including HIV K KH Y Lecture, SGD Written/Viva voce
Obj. 6 At the end of session phase II student must be able to describe the contraindication of the drugs used in UTI/STD and viral disease including HIV K KH Y Lecture, SGD Written/Viva voce
PH1.49 Describe mechanism of action, classes, side effects, indications
and contraindications of anticancer drugs
K KH Y Lecture Written/Viva voce
Obj. 1 At the end of session phase II student must be able to describe the mechanism of action of the anticancer drugs K KH Y Lecture Written/Viva voce
Obj. 2 At the end of session phase II student must be able to classify the anticancer drugs K KH Y Lecture Written/Viva voce
Obj. 3 At the end of session phase II student must be able to describe the side effects of the anticancer drugs K KH Y Lecture Written/Viva voce
Obj. 4 At the end of session phase II student must be able to describe the indications of the anticancer drugs K KH Y Lecture Written/Viva voce
Obj. 5 At the end of session phase II student must be able to describe the contraindication of the anticancer drugs K KH Y Lecture Written/Viva voce
PH1.50 Describe mechanisms of action, types, doses, side effects,
indications and contraindications of immunomodulators and
management of organ transplant rejection
K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of session a phase II student must be able to define immunomodulators K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of session a phase II student must be able to classify immunomodulators K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of session a phase II student must be able to describe the mechanism of action of immunosuppressants K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of session a phase II student must be able to describe the mechanism of action of immunostimulants K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of session a phase II student must be able to enumerate various indications of immunosuppressants K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of session a phase II student must be able to enumerate various indications of immunostimulants K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of session a phase II student must be able to enumerate contraindications of immunomodulators K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of session a phase II student must be able to enumerate side effects of immunomodulators K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of session a phase II student must be able to define graft vs. host disease K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of session a phase II student must be able to enumerate drugs used for graft vs. host disease K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of session a phase II student must be able to describe the management of organ transplant rejection K KH Y Lecture Written/ Viva voce
PH1.51 Describe occupational and environmental pesticides, food
adulterants, pollutants and insect repellents
K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to  enumerate occupational pesticides  K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to  enumerate environmental  pesticides  K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to  enumerate food adulterants K KH Y Lecture Written/ Viva voce
PH1.52 Describe management of common poisoning, insecticides,
common sting and bites
K KH Y SGD Written/ Viva voce General Medicine
Obj. 1 At the end of the session Phase II student must be able to  describe the principles for initial  management of poisoning K KH Y SGD Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to  enumerate antidotes for  common poisonings  K KH Y SGD Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to  describe  management of organophosphorus poisoning  K KH Y SGD Written/ Viva voce
PH1.53 Describe heavy metal poisoning and chelating agents K KH N Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to  enumerate  chelating agents with their clinical use K KH N Lecture Written/ Viva voce
Obj. 2 At the end of session a phase II student must be able to enumerate various antidotes for heavy metal poisoning K KH N Lecture Written/ Viva voce
Obj. 3 At the end of session a phase II student must be able to describe lead poisoning K KH N Lecture Written/ Viva voce
Obj. 4 At the end of session a phase II student must be able to describe iron overload K KH N Lecture Written/ Viva voce
Obj. 5 At the end of session a phase II student must be able to describe arsenic poisoning K KH N Lecture Written/ Viva voce
Obj. 6 At the end of session a phase II student must be able to describe mercury poisoning K KH N Lecture Written/ Viva voce
Obj. 7 At the end of session a phase II student must be able to describe copper poisoning K KH N Lecture Written/ Viva voce
PH1.54 Describe vaccines and their uses K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to  enumerate  types of vaccines with examples K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to  describe national immunization schedule of children   K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to  describe national immunization schedule of adults   K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to  describe national immunization schedule of pregnant female   K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to  enumerate  types of immunoglobulins with examples K KH Y Lecture Written/ Viva voce
PH1.55 Describe and discuss the following National Health Programmes
including Immunisation, Tuberculosis, Leprosy, Malaria, HIV,
Filaria, Kala Azar, Diarrhoeal diseases, Anaemia & nutritional
disorders, Blindness, Non-communicable diseases, cancer and
Iodine deficiency
K KH Y SGD Written/ Viva voce Community Medicine
Obj. 1 At the end of session a phase II student must be able to describe national health program for immunization K KH/S Y SGD Written/ Viva voce
Obj. 2 At the end of session a phase II student must be able to describe national health program for tuberculosis K KH/S Y SGD Written/ Viva voce
Obj. 3 At the end of session a phase II student must be able to describe national health program for leprosy K KH/S Y SGD Written/ Viva voce
Obj. 4 At the end of session a phase II student must be able to describe national health program for malaria K KH/S Y SGD Written/ Viva voce
Obj. 5 At the end of session a phase II student must be able to describe national health program for HIV K KH/S Y SGD Written/ Viva voce
Obj. 6 At the end of session a phase II student must be able to describe national health program for filaria K KH/S Y SGD Written/ Viva voce
Obj. 7 At the end of session a phase II student must be able to describe national health program for kala azar K KH/S Y SGD Written/ Viva voce
Obj. 8 At the end of session a phase II student must be able to describe national health program for diarrhoeal diseases K KH/S Y SGD Written/ Viva voce
Obj. 9 At the end of session a phase II student must be able to describe national health program for anemia K KH/S Y SGD Written/ Viva voce
Obj. 10 At the end of session a phase II student must be able to describe national health program for nutritional disorders K KH/S Y SGD Written/ Viva voce
Obj. 11 At the end of session a phase II student must be able to describe national health program for blindness K KH/S Y SGD Written/ Viva voce
Obj. 12 At the end of session a phase II student must be able to describe national health program for non-communicable diseases K KH/S Y SGD Written/ Viva voce
Obj. 13 At the end of session a phase II student must be able to describe national health program for cancer K KH/S Y SGD Written/ Viva voce
Obj. 14 At the end of session a phase II student must be able to describe national health program for iodine deficiency K KH/S Y SGD Written/ Viva voce
PH1.56 Describe basic aspects of Geriatric and Pediatric pharmacology K KH Y Lecture Written/ Viva voce Pediatrics
Obj. 1 At the end of the session Phase II student must be able to  enumerate pharmacokinetic  factors associated with ageing K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to  enumerate pharmacokinetic  factors affecting drug dose in children K KH Y Lecture Written/ Viva voce
PH1.57 Describe drugs used in skin disorders K KH Y Lecture Written/ Viva voce Dermatology,
Venereology &
Leprosy
Obj. 1 At the end of the session Phase II student must be able to  define demulscents with two examples  K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to  define emolients with two examples  K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to  define astringents  with two examples  K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to  describe mechanism of action of counterirritants  with two examples  K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to  define keratolytics with two examples  K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to  enumerate antiseborrheic  agents with examples   K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to  enumerate drugs for psoriasis   K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to   describe role of PUVA in psoriasis   K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to  enumerate drugs for acnevulgaris K KH Y Lecture Written/ Viva voce
PH1.58 Describe drugs used in Ocular disorders K KH Y Lecture Written/ Viva voce Ophthalmology
Obj. 1 At the end of the session Phase II student must be able to enumerate effect of autonomic drugs on pupil K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to enumerate  topical antibiotics used for various ocular conditions   K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to enumerate  topical antifungals used for various ocular conditions   K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to enumerate  topical glucocorticoids used for various ocular conditions   K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate  topical antihistaminics used for various ocular conditions   K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to  classify glaucoma   K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to enumerate  drugs for open angle glaucoma   K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to enumerate  drugs for close angle glaucoma   K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to write a prescription for open angle glaucoma   K KH Y SGD Written/ Viva voce
PH1.59 Describe and discuss the following: Essential medicines, Fixed dose combinations, Over the counter drugs, Herbal medicines K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to define essential medicines K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to describe the concept of essential medicines K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe the rational of fixed dose combination K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe the advantages  of fixed dose combination K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe the disadvantages of fixed dose combination K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to define over the counter drugs  K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe the clinical relevance of over the counter drugs  K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to enumerate herbal medicines  K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to enumerate therapeutic uses of herbal medicines  K KH Y Lecture Written/ Viva voce
PH1.60 Describe and discuss Pharmacogenomics and
Pharmacoeconomics
K KH N Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to define pharmacogenomics K KH N Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to define pharmacogenetics K KH N Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to enumerate the  examples of pharmacogenomics with their clinical relevance K KH N Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to enumerate the  examples of pharmacogenetics with their clinical relevance K KH N Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to define pharmacoeconomics K KH N Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to describe pharmacoeconomic analysis  K KH N Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe pharmacoeconomic analysis in clinical practice K KH N Lecture Written/ Viva voce
PH1.61 Describe and discuss dietary supplements and nutraceuticals K KH N Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to define nutraceuticals K KH N Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to enumerate the  nutraceuticals K KH N Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to enumerate the therapeutic uses of nutraceuticals K KH N Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to enumerate the  dietary supplements K KH N Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to enumerate the therapeutic uses of  dietary supplements K KH N Lecture Written/ Viva voce
PH1.62 Describe and discuss antiseptics and disinfectants K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to define antiseptics  K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to define disinfectants K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to define germicides  K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to classify germicides  K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe the mechanism of action of germicides in general K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to describe the spectrum of activity  of germicides in general K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to enumerate the uses of germicides K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to define ectoparasiticides K KH Y Lecture Written/ Viva voce
Obj. 9 At the end of the session Phase II student must be able to enumerate ectoparasiticides K KH Y Lecture Written/ Viva voce
Obj. 10 At the end of the session Phase II student must be able to describe  mechanism of action of various ectoparasiticides K KH Y Lecture Written/ Viva voce
Obj. 11 At the end of the session Phase II student must be able to enumerate the uses of ectoparasiticides K KH Y Lecture Written/ Viva voce
PH1.63 Describe Drug Regulations, acts and other legal aspects K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to describe drug schedules  K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to describe schedule Y 
PH1.64 Describe overview of drug development, Phases of clinical trials
and Good Clinical Practice
K KH Y Lecture Written/ Viva voce
Obj. 1 At the end of the session Phase II student must be able to describe drug development K KH Y Lecture Written/ Viva voce
Obj. 2 At the end of the session Phase II student must be able to enumerate phases of clinical trial K KH Y Lecture Written/ Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe phase 0 of clinical trial K KH Y Lecture Written/ Viva voce
Obj. 4 At the end of the session Phase II student must be able to describe phase I of clinical trial K KH Y Lecture Written/ Viva voce
Obj. 5 At the end of the session Phase II student must be able to describe phase II of clinical trial K KH Y Lecture Written/ Viva voce
Obj. 6 At the end of the session Phase II student must be able to describe phase III of clinical trial K KH Y Lecture Written/ Viva voce
Obj. 7 At the end of the session Phase II student must be able to describe phase of IV of clinical trial K KH Y Lecture Written/ Viva voce
Obj. 8 At the end of the session Phase II student must be able to enumerate the principles of good clinical practice K KH Y Lecture Written/ Viva voce
SKILLS: Topic: Clinical Pharmacy                          Number of competencies: (04)                                Number of procedures that require certification : (NIL)
PH2.1 Demonstrate understanding of the use of various dosage forms
(oral/local/parenteral; solid/liquid)
S/C SH Y DOAP Skills assessment
Obj. 1 At the end of the session Phase II student must be able to enumerate various types of dosage forms S/C SH Y DOAP Skills assessment
Obj. 2 At the end of the session Phase II student must be able to describe advantages of various dosage forms S/C SH Y DOAP Skills assessment
Obj. 3 At the end of the session Phase II student must be able to describe disadvantages of various dosgae forms S/C SH Y DOAP Skills assessment
Obj. 4 At the end of the session Phase II student must be able to decide in a given clinical situation which dosage form is best suited to the patient S/C SH Y DOAP Skills assessment
Obj. 5 At the end of the session Phase II student must be able to identify various dosage forms S/C SH Y DOAP Skills assessment
Obj. 6 At the end of the session Phase II student must be able to demostrate the applications of the given dosage form S/C SH Y DOAP Skills assessment
PH2.2 Prepare oral rehydration solution from ORS packet and explain its
use
S/C SH Y DOAP Skills assessment
Obj. 1 At the end of the session Phase II student must be able to enumerate constituents of ORS S/C SH Y DOAP Skills assessment
Obj. 2 At the end of the session Phase II student must be able to prepare ORS from the given ORS packet correctly S/C SH Y DOAP Skills assessment
Obj. 3 At the end of the session Phase II student must be able to enumerate the benefits of individual constituents S/C SH Y DOAP Skills assessment
Obj. 4 At the end of the session Phase II student must be able to enumerate therapeutic uses of ORS S/C SH Y DOAP Skills assessment
Obj. 5 At the end of the session Phase II student must be able to enumerate precautions to be taken while constituting ORS S/C SH Y DOAP Skills assessment
Obj. 6 At the end of the session Phase II student must be able to enumerate precautions to be taken while using ORS S/C SH Y DOAP Skills assessment
PH2.3 Demonstrate the appropriate setting up of an intravenous drip in a
simulated environment
S SH Y DOAP Skills assessment
Obj. 1 At the end of the session Phase II student must be able to enumerate steps for setting up an IV drip in a mannikin S SH Y DOAP Skills assessment
Obj. 2 At the end of the session Phase II student must be able to setup an IV drip in a mannikin correctly S SH Y DOAP Skills assessment
PH2.4 Demonstrate the correct method of calculation of drug dosage in
patients including those used in special situations
S SH Y DOAP, SGD Skills assessment Pediatrics,
General Medicine
Obj. 1 At the end of the session Phase II student must be able to write the formula to calculate drug dose according to body weight in a particular individual K K Y DOAP, SGD Skills assessment
Obj. 2 At the end of the session Phase II student must be able to write the formula to calculate drug dose in children K K Y DOAP, SGD Skills assessment
Obj. 3 At the end of the session Phase II student must be able to write the formula to calculate drug dose in elderly K K Y DOAP, SGD Skills assessment
Obj. 4 At the end of the session Phase II student must be able to write the formula to calculate drug dose in patient with renal dysfunction K K Y DOAP, SGD Skills assessment
Obj. 5 At the end of the session Phase II student must be able to calculate the drug dose according to body weight in a particular individual K/S KH Y DOAP, SGD Skills assessment
Obj. 6 At the end of the session Phase II student must be able to calculate drug dose in elderly K/S KH Y DOAP, SGD Skills assessment
Obj. 7 At the end of the session Phase II student must be able to calculate drug dose in children K/S KH Y DOAP, SGD Skills assessment
Obj. 8 At the end of the session Phase II student must be able to calculate drug dose in patient with renal dysfunction K/S KH Y DOAP, SGD Skills assessment
SKILLS: Topic: Clinical Pharmacology                  Number of competencies: (08)                                Number of procedures that require certification : (04)
PH3.1 Write a rational, correct and legible generic prescription for a given
condition and communicate the same to the patient
S/C P Y SGD, DOAP Skill station 5 General Medicine
Obj. 1 At the end of the session Phase II student must be able to  enumerate various components of an ideal prescription S/C P Y SGD, DOAP Skill station
Obj. 2 At the end of the session Phase II student must be able to write a correct legible generic prescription for a given condition S/C P Y SGD, DOAP Skill station
Obj. 3 At the end of the session Phase II student must be able to write the rationale for the medicines prescribed S/C P Y SGD, DOAP Skill station
Obj. 4 At the end of the session Phase II student must be able to enumerate various ADRs because of given prescription S/C P Y SGD, DOAP Skill station
Obj. 5 At the end of the session Phase II student must be able to write the rationale for various instructions given in the prescription S/C P Y SGD, DOAP Skill station
Obj. 6 At the end of the session Phase II student must be able to communicate the given prescription to a valunteer S/C P Y SGD, DOAP Skill station
PH3.2 Perform and interpret a critical appraisal (audit) of a given
prescription
S P Y DOAP Maintenance of log book 3
Obj. 1 At the end of the session Phase II student must be able to enumerate various components of a prescription to be audited as per WHO guidelines S P Y DOAP Maintenance of log book
Obj. 2 At the end of the session Phase II student must be able to find the correct components in a given prescription S P Y DOAP Maintenance of log book
Obj. 3 At the end of the session Phase II student must be able to identify the incorrect components in a given prescription S P Y DOAP Maintenance of log book
Obj. 4 At the end of the session Phase II student must be able to identify the missing components in a given prescription S P Y DOAP Maintenance of log book
Obj. 5 At the end of the session Phase II student must be able to document the findings of critical appraisal of a given prescription S P Y DOAP Maintenance of log book
Obj. 6 At the end of the session Phase II student must be able to grade the given prescription S P Y DOAP Maintenance of log book
PH3.3 Perform a critical evaluation of the drug promotional literature S P Y SGD, DOAP Maintenance of log book/
Skill station
3 General Medicine
Obj. 1 At the end of the session Phase II student must be able to enumerate various essential parts of DPL as per WHO guidelines S P Y SGD, DOAP Maintenance of log book/
Skill station
Obj. 2 At the end of the session Phase II student must be able to find the correct components in a given DPL S P Y SGD, DOAP Maintenance of log book/
Skill station
Obj. 3 At the end of the session Phase II student must be able to identify the incorrect components in a given DPL S P Y SGD, DOAP Maintenance of log book/
Skill station
Obj. 4 At the end of the session Phase II student must be able to identify the missing components in a given DPL S P Y SGD, DOAP Maintenance of log book/
Skill station
Obj. 5 At the end of the session Phase II student must be able to document the findings of critical appraisal of a given DPL S P Y SGD, DOAP Maintenance of log book/
Skill station
PH3.4 To recognise and report an adverse drug reaction S SH Y DOAP Maintenance of log book/
Skill station
Obj. 1 At the end of session a phase II student must be able to define adverse drug reaction S SH Y DOAP Maintenance of log book/
Skill station
Obj. 2 At the end of session a phase II student must be able to define adverse drug event S SH Y DOAP Maintenance of log book/
Skill station
Obj. 3 At the end of session a phase II student must be able to describe basic principles of causality assessment S SH Y DOAP Maintenance of log book/
Skill station
Obj. 4 At the end of session a phase II student must be able to describe basic principles of management of adverse drug reactions S SH Y DOAP Maintenance of log book/
Skill station
Obj. 5 At the end of session a phase II student must be able to WHO scale of causality assessment S SH Y DOAP Maintenance of log book/
Skill station
Obj. 6 At the end of session a phase II student must be able to fill the WHO Adverse drug reaction form correctly based on given clinical situations S SH Y DOAP Maintenance of log book/
Skill station
PH3.5 To prepare and explain a list of P-drugs for a given case/condition S P Y DOAP,SGD Maintenance of log book 3 General Medicine
Obj. 1 At the end of the session Phase II student must be able to enumerate steps for preparation of P-drugs S P Y DOAP,SGD Maintenance of log book
Obj. 2 At the end of the session Phase II student must be able to prepare a list of P-drugs for a given clinical situation S P Y DOAP,SGD Maintenance of log book
Obj. 3 At the end of the session Phase II student must be able to explain list of P-drugs for a given clinical situation to a volunteer S P Y DOAP,SGD Maintenance of log book
PH3.6 Demonstrate how to optimize interaction with pharmaceutical
representative to get authentic information on drugs
S SH N Small group discussion Maintenance of log book
Obj. 1 At the end of the session Phase II student must be able to enumerate various parts of communication to a MR S SH N Small group discussion Maintenance of log book
PH3.7 Prepare a list of essential medicines for a healthcare facility S SH Y DOAP, SGD Maintenance of log book
Obj. 1 At the end of the session Phase II student must be able to enumerate the steps for preparation of essential medicine list for a healthcare facility S SH Y DOAP, SGD Maintenance of log book
Obj. 2 At the end of the session Phase II student must be able to prepare a list of essential medicine for a healthcare facility using the standard steps S SH Y DOAP, SGD Maintenance of log book
PH3.8 Communicate effectively with a patient on the proper use of
prescribed medication
C/A SH Y Small group discussion Skill station
Obj. 1 At the end of the session Phase II student must be able to communicate effectively to a patient with proper use of prescribed medicine C/A SH Y Small group discussion Skill station
SKILLS: Topic: Experimental Pharmacology           Number of competencies: (02)                            Number of procedures that require certification :(NIL)
PH4.1 Administer drugs through various routes in a simulated
environment using mannequins
S SH Y DOAP Skills assessment
Obj. 1 At the end of the session Phase II student must be able to enumerate various routes of administration of medicines S SH Y DOAP Skills assessment
Obj. 2 At the end of the session Phase II student must be able to write the steps for administering the medicine with a given route in the mannequin S SH Y DOAP Skills assessment
Obj. 3 At the end of the session Phase II student must be able to administer the medicine using the given route in the mannequin S SH Y DOAP Skills assessment
PH4.2 Demonstrate the effects of drugs on blood pressure (vasopressor
and vaso-depressors with appropriate blockers) using computer
aided learning
S SH Y DOAP Skill station
Obj. 1 At the end of the session Phase II student must be able to enumerate the effects of given drug on dog BP S SH Y DOAP Skill station
Obj. 2 At the end of the session Phase II student must be able to enumerate the steps for demonstrating the effects of drug on dog BP using CAL S SH Y DOAP Skill station
Obj. 3 At the end of the session Phase II student must be able to demonstrate the effect of given drug S SH Y DOAP Skill station
Obj. 4 At the end of the session Phase II student must be able to demonstrate the effect of given drug on dog BP using CAL S SH Y DOAP Skill station
Obj. 5 At the end of the session Phase II student must be able to identify the unknown drug in a given pictogram S SH Y DOAP Skill station
Communication Topic: Pharmacology                    Number of competencies: (07)                             Number of procedures that require certification : (NIL)
PH5.1 Communicate with the patient with empathy and ethics on all
aspects of drug use
A/C SH Y Small group discussion skill station General Medicine
Obj. 1 At the end of the session Phase II student must be able to communicate with the patient with empathy on all the aspects of drug use A/C SH Y Small group discussion skill station
Obj. 2 At the end of the session Phase II student must be able to communicate with the patient with ethics on all the aspects of drug use A/C SH Y Small group discussion skill station
PH5.2 Communicate with the patient regarding optimal use of a) drug
therapy, b) devices and c) storage of medicines
A/C SH Y Small group discussion Skill station
Obj. 1 At the end of the session Phase II student must be able to communicate with the patient regarding optimal use of drug therapy A/C SH Y Small group discussion Skill station
Obj. 2 At the end of the session Phase II student must be able to communicate with the patient regarding optimal use of devices A/C SH Y Small group discussion Skill station
Obj. 3 At the end of the session Phase II student must be able to communicate with the patient regarding optimal use of storage of medicines A/C SH Y Small group discussion Skill station
PH5.3 Motivate patients with chronic diseases to adhere to the prescribed
management by the health care provider
A/C SH Y Small group discussion short note/skill station
Obj. 1 At the end of the session Phase II student must be able to enumerate reasons for non-compliance of medicines A/C SH Y Small group discussion short note/skill station
Obj. 2 At the end of the session Phase II student must be able to enumerate essential components of communication to improve compliance A/C SH Y Small group discussion short note/skill station
PH5.4 Explain to the patient the relationship between cost of treatment
and patient compliance
A/C SH Y Small group discussion short note/ viva voce General Medicine
Obj. 1 At the end of the session Phase II student must be able to describe the relationship between cost of treatment and patient compliance A/C SH Y Small group discussion short note/ viva voce
Obj. 2 At the end of the session Phase II student must be able to explain to a volunteer the relationship between cost of treatment and patient compliance A/C SH Y Small group discussion short note/ viva voce
PH5.5 Demonstrate an understanding of the caution in prescribing drugs
likely to produce dependence and recommend the line of
management
K KH Y Small group discussion short note/ viva voce Psychiatry
Obj. 1 At the end of the session Phase II student must be able to define drug dependence K KH Y Small group discussion short note/ viva voce
Obj. 2 At the end of the session Phase II student must be able to enumerate drugs more prone to develop drug dependence K KH Y Small group discussion short note/ viva voce
Obj. 3 At the end of the session Phase II student must be able to write the steps for the management for drug dependence K KH Y Small group discussion short note/ viva voce
Obj. 4 At the end of the session Phase II student must be able to write the mechanism of drug dependence K KH Y Small group discussion short note/ viva voce
Obj. 5 At the end of the session Phase II student must be able to describe various types of drug dependence K KH Y Small group discussion short note/ viva voce
Obj. 6 At the end of the session Phase II student must be able to enumerate drugs causing physical dependence K KH Y Small group discussion short note/ viva voce
Obj. 7 At the end of the session Phase II student must be able to enumerate drugs causing psychological dependence K KH Y Small group discussion short note/ viva voce
PH5.6 Demostrate ability to educate public & patients about various aspects of drug use including drug dependence and OTC drugs A/C SH Y Small group discussion skill station Psychiatry
Obj. 1 At the end of session phase II student must be able to enumerate the essential components to public about OTC drugs A/C SH Y Small group discussion skill station
Obj. 2 At the end of the session Phase II student must be able to enumerate various components about drugs causing dependence A/C SH Y Small group discussion skill station
Obj. 3 At the end of the session Phase II student must be able to demonstrate the ability of creating awareness about drugs causing dependence A/C SH Y Small group discussion skill station
Obj. 4 At the end of the session Phase II student must be able to demonstrate the ability of creating awareness about drugs causing dependence to the students present in the class A/C SH Y Small group discussion skill station
Obj. 5 At the end of the session Phase II student must be able to demonstrate the ability of creating awareness about OTC drugs A/C SH Y Small group discussion skill station
PH5.7 Demostrate an understanding of the legal and ethical aspects of prescribing drugs K KH Y Small group discussion short note/Viva voce Forensic Medicine
Obj. 1 At the end of the session Phase II student must be able to describe the components of schedule H K KH Y Small group discussion short note/Viva voce
Obj. 2 At the end of the session Phase II student must be able to describe the various schedules of drugs and cosmetic act K KH Y Small group discussion short note/Viva voce
Obj. 3 At the end of the session Phase II student must be able to describe the legal importance of prescription K KH Y Small group discussion short note/Viva voce
Obj. 4 At the end of the session Phase II student must be able to enumerate various components of a prescription to make it legally acceptable K KH Y Small group discussion short note/Viva voce
Obj. 5 At the end of the session Phase II student must be able to identify unnecessary drugs in a given prescription K KH Y Small group discussion short note/Viva voce
Obj. 6 At the end of the session Phase II student must be able to identify the drugs for which cheaper alternatives are available using MIMS K KH Y Small group discussion short note/Viva voce
Obj. 7 At the end of the session Phase II student must be able to replace the drug with a cheaper alternative K KH Y Small group discussion short note/Viva voce
Obj. 8 At the end of the session Phase II student must be able to describe various components of ethics by MCI K KH Y Small group discussion short note/Viva voce